CN1351081A - Human protein with cancer cell growth suppressing function and its coding sequence - Google Patents

Abstract

A novel human protein with cancer suppressing function, the polynucleotide for coding it, the process for preparing said polypeptide by recombination, the application of said polypeptide in treating diseases such as cancer, etc, the antagon of said polypeptide and its medical action, and the application of said polynucleotide are disclosed.

Description

New people's albumen and encoding sequence thereof with anticancer growth function

The invention belongs to biological technical field, specifically, the present invention relates to the proteic polynucleotide of people that new coding has cancer suppressing function, and the polypeptide of this polynucleotide encoding.The invention still further relates to the purposes and the preparation of these polynucleotide and polypeptide.

The research of people's gene group is international focus at present, removes human chromosome DNA large scale sequencing, outside the method for expressed sequence order-checking (EST), also lacks the screening that begins from function and has the high-throughout method of functional gene.

Cancer is one of principal disease of harm humans health.In order to treat effectively and prophylaxis of tumours, people more and more pay close attention to genetic treatment of tumor at present.Therefore, this area presses for people's albumen and the agonist/inhibitor thereof that development research has cancer suppressing function.

The purpose of this invention is to provide the new people's protein polypeptide of a class with cancer suppressing function with and fragment, analogue and derivative.

Another object of the present invention provides the polynucleotide of these polypeptide of coding.

Another object of the present invention provides the method for these polypeptide of production and the purposes of this polypeptide and encoding sequence.

In a first aspect of the present invention, novel isolated protein polypeptide with cancer suppressing function is provided, and it comprises the polypeptide of the aminoacid sequence with the group of being selected from down: SEQ ID NO:2, SEQ ID NO:5, SEQ ID NO:8, SEQ IDNO:11, SEQ ID NO:14, SEQ ID NO:17, SEQ ID NO:20, SEQ ID NO:23, SEQ ID NO:26, SEQ ID NO:29; Or its conservative property variation polypeptide or its active fragments or its reactive derivative.

Preferably, this polypeptide is the polypeptide with aminoacid sequence of the group of being selected from down: SEQ ID NO:2, SEQ ID NO:5, SEQ ID NO:8, SEQ ID NO:11, SEQ ID NO:14, SEQ ID NO:17, SEQ ID NO:20, SEQ IDNO:23, SEQ ID NO:26, SEQ ID NO:29.

In a second aspect of the present invention, a kind of isolating polynucleotide are provided, it comprises a nucleotide sequence, and this nucleotide sequence is shown at least 85% homogeny with a kind of nucleotides sequence that is selected from down group: the polynucleotide of the above-mentioned protein polypeptide with cancer suppressing function of (a) encoding; (b) with polynucleotide (a) complementary polynucleotide.Preferably, the polypeptide of this polynucleotide encoding has the aminoacid sequence of the group of being selected from down: SEQ ID NO:2, SEQ ID NO:5, SEQ D NO:8, SEQ IDNO:11, SEQ ID NO:14, SEQ ID NO:17, SEQ ID NO:20, SEQ ID NO:23, SEQ ID NO:26, SEQ ID NO:29.More preferably, the sequence of these polynucleotide is selected from down group: coding region sequence or the full length sequence of SEQ ID NO:3, SEQ ID NO:6, SEQID NO:9, SEQ ID NO:12, SEQ ID NO:15, SEQ ID NO:18, SEQ ID NO:21, SEQ ID NO:24, SEQ ID NO:27, SEQ ID NO:30.

In a third aspect of the present invention, the carrier that contains above-mentioned polynucleotide is provided, and has been transformed or host cell of transduceing or the host cell that is directly transformed or transduce by above-mentioned polynucleotide by this carrier.

In a fourth aspect of the present invention, the preparation method who prepares the polypeptide of the protein-active with cancer suppressing function is provided, this method comprises: (a) have under the proteic condition of cancer suppressing function suitable the expression, cultivate the above-mentioned host cell that is transformed or transduce; (b) from culture, isolate the polypeptide of protein-active with cancer suppressing function.

In a fifth aspect of the present invention, provide and above-mentioned protein polypeptide specificity bonded antibody with cancer suppressing function.The nucleic acid molecule that can be used for detecting also is provided, and it contains, and continuous 10 Nucleotide are to full length nucleotide in the above-mentioned polynucleotide, and preferably it contains the about 10-800 of a successive Nucleotide.

In a sixth aspect of the present invention, a kind of pharmaceutical composition is provided, it contains the protein polypeptide and the pharmaceutically acceptable carrier with cancer suppressing function of the present invention of safe and effective amount.These pharmaceutical compositions can be treated illnesss such as cancer and cellular abnormality propagation.

Others of the present invention are because disclosing of the technology of this paper is conspicuous to those skilled in the art.

The present invention adopts large-scale cDNA clone transfection cancer cells, has on the basis of cancer suppressing action in acquisition, proves new gene through order-checking, further obtains full length cDNA clone.DNA transfection evidence, the albumen with cancer suppressing function of the present invention has the effect that suppresses clone's formation to cancer cells (liver cancer cell), and its inhibiting rate is more than 50% or 50%.

As used herein, " isolating " is meant that material separates (if natural substance, primal environment promptly is a natural surroundings) from its primal environment.Do not have separation and purification as polynucleotide under the native state in the active somatic cell and polypeptide, but same polynucleotide or polypeptide as from native state with in other materials that exist separately, then for separation and purification.

As used herein, " isolating albumen or polypeptide with cancer suppressing function " is meant that the protein polypeptide with cancer suppressing function is substantially free of natural relative other albumen, lipid, carbohydrate or other material.Those skilled in the art can have the albumen of cancer suppressing function with the purified technology of protein purifying of standard.Basically pure polypeptide can produce single master tape on non-reduced polyacrylamide gel.Purity with protein polypeptide of cancer suppressing function can be used amino acid sequence analysis.

Polypeptide of the present invention can be recombinant polypeptide, natural polypeptides, synthetic polypeptide, preferred recombinant polypeptide.Polypeptide of the present invention can be the product of natural purifying, or the product of chemosynthesis, or uses recombinant technology to produce from protokaryon or eucaryon host (for example, bacterium, yeast, higher plant, insect and mammalian cell).The host used according to the recombinant production scheme, polypeptide of the present invention can be glycosylated, maybe can be nonglycosylated.Polypeptide of the present invention also can comprise or not comprise initial methionine residues.

The present invention also comprises the proteic fragment of the people with cancer suppressing function, derivative and analogue.As used herein, term " fragment ", " derivative " are meant with " analogue " and keep natural identical biological function or the active polypeptide of people's albumen with cancer suppressing function of the present invention basically.Polypeptide fragment of the present invention, derivative or analogue can be that (i) has one or more conservative or substituted polypeptide of non-conservation amino-acid residue (preferred conservative amino acid residue), and the amino-acid residue of such replacement can be also can not encoded by genetic code, or (ii) in one or more amino-acid residues, has a polypeptide of substituted radical, or (iii) mature polypeptide and another compound (such as the compound that prolongs the polypeptide transformation period, polyoxyethylene glycol for example) merge formed polypeptide, or (iv) additional aminoacid sequence is fused to this peptide sequence and the polypeptide that forms (as leader sequence or secretion sequence or be used for the sequence or the proteinogen sequence of this polypeptide of purifying).According to the instruction of this paper, these fragments, derivative and analogue belong to the known scope of those skilled in the art.

Polynucleotide of the present invention can be dna form or rna form.Dna form comprises the DNA of cDNA, genomic dna or synthetic.DNA can be strand or double-stranded.DNA can be coding strand or noncoding strand.Be example with PP7027 albumen (in this application, its clone numbering is adopted in proteinic name), the coding region sequence of encoding mature polypeptide can be identical with the coding region sequence shown in the SEQ ID NO:3 or the varient of degeneracy.As used herein, " varient of degeneracy " is meant that in the present invention coding has the protein of SEQ ID NO:2, but with the coding region sequence shown in the SEQ IDNO:3 other nucleotide sequence of difference arranged.Be example with PP7059 albumen (in this application, its clone numbering is adopted in proteinic name), the coding region sequence of encoding mature polypeptide can be identical with the coding region sequence shown in the SEQ ID NO:6 or the varient of degeneracy.As used herein, " varient of degeneracy " is meant that in the present invention coding has the protein of SEQ ID NO:5, but with the differentiated nucleotide sequence of coding region sequence shown in the SEQ ID NO:6.Have the albumen of cancer suppressing function for other, can the rest may be inferred.Have the albumen of cancer suppressing function for other, can the rest may be inferred.

The polynucleotide of encoding mature polypeptide comprise: the encoding sequence of an encoding mature polypeptide; The encoding sequence of mature polypeptide and various additional code sequence; Encoding sequence of mature polypeptide (with optional additional code sequence) and non-coding sequence.

Term " polynucleotide of coded polypeptide " can be the polynucleotide that comprise this polypeptide of encoding, and also can be the polynucleotide that also comprise additional code and/or non-coding sequence.

The invention still further relates to the varient of above-mentioned polynucleotide, its coding has the polypeptide of identical aminoacid sequence or fragment, analogue and the derivative of polypeptide with the present invention.The varient of these polynucleotide can be the allelic variant of natural generation or the varient that non-natural takes place.These nucleotide diversity bodies comprise and replace varient, deletion mutation body and insert varient.As known in the art, allelic variant is the replacement form of polynucleotide, and it may be replacement, disappearance or the insertion of one or more Nucleotide, but can be from not changing the function of its encoded polypeptides in fact.

The invention still further relates to and above-mentioned sequence hybridization and two sequences between have at least 50%, preferably at least 70%, the polynucleotide of at least 80% homogeny more preferably.The present invention be more particularly directed under stringent condition and the interfertile polynucleotide of polynucleotide of the present invention.In the present invention, " stringent condition " is meant: (1) than hybridization under low ionic strength and the comparatively high temps and wash-out, as 0.2 * SSC, and 0.1%SDS, 60 ℃; Or (2) hybridization the time is added with denaturing agent, as 50% (v/v) methane amide, 0.1% calf serum/0.1%Ficoll, 42 ℃ etc.; Or (3) only at the homogeny between the two sequences at least more than 95%, be more preferably 97% and just hybridize when above.And the polypeptide of interfertile polynucleotide encoding has identical biological function (is example with PP7027 albumen) and activity with the mature polypeptide shown in the SEQ IDNO:2.

The invention still further relates to nucleic acid fragment with above-mentioned sequence hybridization.As used herein, the length of " nucleic acid fragment " contains 15 Nucleotide at least, better is at least 30 Nucleotide, is more preferably at least 50 Nucleotide, preferably more than at least 100 Nucleotide.The amplification technique (as PCR) that nucleic acid fragment can be used for nucleic acid has the proteic polynucleotide of cancer suppressing function to determine and/or to separate to encode.

Polypeptide among the present invention and polynucleotide preferably provide with isolating form, more preferably are purified to homogeneous.

Dna sequence dna of the present invention can obtain with several method.For example, with hybridization technique DNA isolation well known in the art.These technology including, but not limited to: 1) with probe and genome or the hybridization of cDNA library to detect homology nucleotide sequence and 2) antibody screening of expression library to be to detect the dna fragmentation of the clone with common structure feature.

The proteic specific DNA fragment sequence that coding has cancer suppressing function produces also and can obtain with following method: 1) separate double chain DNA sequence from genomic dna; 2) the chemical synthesising DNA sequence is to obtain the double-stranded DNA of required polypeptide.

In the above-mentioned method of mentioning, isolation of genomic DNA is least commonly used.When the whole aminoacid sequence of the polypeptide product of needs was known, the direct chemical of dna sequence dna is synthetic to be the method for often selecting for use.When if required amino acid whose whole sequence is not known, the direct chemical of dna sequence dna is synthetic to be impossible, and the method for selecting for use is the separation of cDNA sequence.The standard method that separates interested cDNA is from the donorcells separating mRNA of this gene of high expression level and carries out reverse transcription, forms plasmid or phage cDNA library.Extract the existing multiple proven technique of method of mRNA, test kit also can obtain (Qiagene) from commercial channels.And the construction cDNA library also is usual method (Sambrook, et al., Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Laboratory.New York, 1989).Also can obtain the cDNA library of commercial offers, as the different cDNA library of Clontech company.When being used in combination the polymeric enzyme reaction technology, even few expression product also can be cloned.

Available ordinary method is screened gene of the present invention from these cDNA libraries.These methods include, but is not limited to: (1) DNA-DNA or DNA-RNA hybridization; (2) function of marker gene occurs or forfeiture; (3) mensuration has the level of the proteic transcript of cancer suppressing function; (4), detect the protein product of genetic expression by immunological technique or mensuration biologic activity.Aforesaid method can singly be used, but also several different methods combined utilization.

In (1) kind method, hybridizing used probe is and any a part of homology of polynucleotide of the present invention that at least 15 Nucleotide of its length better are at least 30 Nucleotide, are more preferably at least 50 Nucleotide, preferably at least 100 Nucleotide.In addition, the length of probe within 2kb, preferably is within the 1kb usually.Probe used herein is the dna sequence dna of chemosynthesis on the basis of gene DNA sequence information of the present invention normally.Gene of the present invention itself or fragment are certainly as probe.The mark of dna probe can be used radio isotope, fluorescein or enzyme (as alkaline phosphatase) etc.

In (4) kind method, detect the protein product of protein gene expression and can use immunological technique such as Western blotting, radioimmunoprecipitation, enzyme-linked immunosorbent assay (ELISA) etc. with cancer suppressing function.

Use method (Saiki, the et al.Science 1985 of round pcr DNA amplification/RNA; 230:1350-1354) be optimized for acquisition gene of the present invention.When particularly being difficult to obtain the cDNA of total length from the library, can preferably use RACE method (the terminal rapid amplifying method of RACE-cDNA), the primer that is used for PCR can suitably be selected according to sequence information of the present invention disclosed herein, and available ordinary method is synthetic.Available ordinary method is as the DNA/RNA fragment by gel electrophoresis separation and purifying amplification.

The gene of the present invention that obtains as mentioned above, perhaps the available ordinary method of mensuration of the nucleotide sequence of various dna fragmentations etc. such as dideoxy chain termination (Sanger et al.PNAS, 1977,74:5463-5467).This class nucleotide sequencing is available commercial sequencing kit etc. also.In order to obtain the cDNA sequence of total length, order-checking need be carried out repeatedly.Sometimes need to measure a plurality of clones' cDNA sequence, just can be spliced into the cDNA sequence of total length.

The present invention also relates to comprise the carrier of polynucleotide of the present invention, and the host cell that produces through genetically engineered with carrier of the present invention or albumen coded sequence with cancer suppressing function, and the method that produces polypeptide of the present invention through recombinant technology.

Recombinant DNA technology (Science, 1984 by routine; 224:1431), can utilize polymerized nucleoside acid sequence of the present invention to can be used to express or produce the protein polypeptide with cancer suppressing function of reorganization.In general following steps are arranged:

(1). have the proteic polynucleotide of people (or varient) of cancer suppressing function with coding of the present invention, or transform or the transduction proper host cell with the recombinant expression vector that contains these polynucleotide;

(2). the host cell of in suitable medium, cultivating;

(3). separation, protein purification from substratum or cell.

Among the present invention, the people's albumen polynucleotide sequence with cancer suppressing function can be inserted in the recombinant expression vector.Term " recombinant expression vector " refers to that bacterial plasmid well known in the art, phage, yeast plasmid, vegetable cell virus, mammalian cell virus are as adenovirus, retrovirus or other carriers.The carrier of Shi Yonging includes but not limited in the present invention: and the expression vector based on T7 of in bacterium, expressing (Rosenberg, et al.Gene, 1987,56:125); The pMSXND expression vector of in mammalian cell, expressing (Lee and Nathans, J Bio Chem.263:3521,1988) and at the carrier that derives from baculovirus of expressed in insect cells.In a word, as long as can duplicate in host and stablize, any plasmid and carrier can be used.A key character of expression vector is to contain replication orgin, promotor, marker gene and translation controlling elements usually.

Method well-known to those having ordinary skill in the art can be used to make up and contains people's encoding histone dna sequence dna with cancer suppressing function and suitable transcribing/the translate expression vector of control signal.These methods comprise (Sambroook, et al.Molecular Cloning, a Laboratory Manual, coldSpring Harbor Laboratory.New York, 1989) such as extracorporeal recombinant DNA technology, DNA synthetic technology, the interior recombinant technologys of body.Described dna sequence dna can effectively be connected on the suitable promotor in the expression vector, and is synthetic to instruct mRNA.The representative example of these promotors has: colibacillary lac or trp promotor; Lambda particles phage P _LPromotor; Eukaryotic promoter comprises LTRs and some other known may command gene expression promoter in protokaryon or eukaryotic cell or its virus of CMV immediate early promoter, HSV thymidine kinase promoter, early stage and late period SV40 promotor, retrovirus.Expression vector also comprises ribosome bind site and the transcription terminator that translation initiation is used.

In addition, expression vector preferably comprises one or more selected markers, to be provided for selecting the phenotypic character of transformed host cells, cultivate Tetrahydrofolate dehydrogenase, neomycin resistance and the green fluorescent protein (GFP) of usefulness as eukaryotic cell, or be used for colibacillary tsiklomitsin or amicillin resistance.

Comprise the carrier of above-mentioned suitable dna sequence dna and suitable promotor or control sequence, can be used to transform appropriate host cell, so that it can marking protein.

Host cell can be a prokaryotic cell prokaryocyte, as bacterial cell; Or eukaryotic cell such as low, as yeast cell; Or higher eucaryotic cells, as mammalian cell.Representative example has: intestinal bacteria, streptomyces; The bacterial cell of Salmonella typhimurium; Fungal cell such as yeast; Vegetable cell; The insect cell of fruit bat S2 or Sf9; The zooblast of CHO, COS or Bowes melanoma cells etc.

When polynucleotide of the present invention are expressed in higher eucaryotic cells, be enhanced if will make to transcribe when in carrier, inserting enhancer sequence.Enhanser is the cis acting factor of DNA, and nearly 10 to 300 base pairs act on promotor transcribing with enhancing gene usually.Can for example be included in the SV40 enhanser of 100 to 270 base pairs of replication origin side in late period one, at the polyoma enhanser of replication origin side in late period one and adenovirus enhanser etc.

Persons skilled in the art all know how to select appropriate carriers, promotor, enhanser and host cell.

Can carry out with routine techniques well known to those skilled in the art with the recombinant DNA transformed host cell.When the host was prokaryotic organism such as intestinal bacteria, the competent cell that can absorb DNA can be used CaCl in exponential growth after date results ₂Method is handled, and used step is well-known in this area.Alternative is to use MgCl ₂If desired, transforming also the method for available electroporation carries out.When the host is an eukaryote, can select following DNA transfection method for use: coprecipitation of calcium phosphate method, conventional mechanical method such as microinjection, electroporation, liposome packing etc.

The transformant that obtains can be cultivated with ordinary method, expresses the polypeptide of coded by said gene of the present invention.According to used host cell, used substratum can be selected from various conventional substratum in the cultivation.Under the condition that is suitable for the host cell growth, cultivate.After host cell grows into suitable cell density, induce the promotor of selection with suitable method (as temperature transition or chemical induction), cell is cultivated for some time again.

Recombinant polypeptide in the above methods can wrap by in cell, extracellular or on cytolemma, express or be secreted into the extracellular.If desired, can utilize its physics, the separating by various separation methods with other characteristic and the albumen of purification of Recombinant of chemistry.These methods are well-known to those skilled in the art.The example of these methods includes, but are not limited to: conventional renaturation handles, with protein precipitant handle (salt analysis method), centrifugal, the broken bacterium of infiltration, superly handle, the combination of super centrifugal, sieve chromatography (gel-filtration), adsorption chromatography, ion exchange chromatography, high performance liquid chromatography (HPLC) and other various liquid chromatography (LC) technology and these methods.

The people's albumen or the polypeptide with cancer suppressing function of reorganization are of use in many ways.These purposes include, but is not limited to: directly have the disease due to the low or forfeiture of the protein function of cancer suppressing function as pharmacological agent and be used to screen and promote or antagonism has antibody, polypeptide or other part of the protein function of cancer suppressing function.For example, antibody can be used for activating or suppressing to have the proteic function of people of cancer suppressing function.The people's protein screening peptide library that has a cancer suppressing function with the reorganization of expressing can be used for seeking the peptide molecule that can suppress or stimulate the people's protein function with cancer suppressing function of therapeutic value.

The present invention also provides screening of medicaments to improve (agonist) or check the method that (antagonist) has the proteic medicament of people of cancer suppressing function to identify.Agonist improves the biological function such as stimulate cellular proliferation of the people's albumen with cancer suppressing function, and antagonist prevention disorder such as the various cancer relevant with cell hyperproliferation with treatment.For example, can be in the presence of medicine, the proteic film preparation of people that mammalian cell or expression is had cancer suppressing function is cultivated with the people's albumen with cancer suppressing function of mark.Measure the medicine raising then or check this interactional ability.

The proteic antagonist of people with cancer suppressing function comprises antibody, compound, acceptor disappearance thing and the analogue etc. that filter out.The proteic antagonist of people with cancer suppressing function can and be eliminated its function with the people's protein binding with cancer suppressing function, or suppresses to have the proteic generation of people of cancer suppressing function, or combines with the avtive spot of polypeptide and to make polypeptide can not bring into play biological function.The proteic antagonist of people with cancer suppressing function can be used for therepic use.

In screening during as the compound of antagonist, the albumen that can have a cancer suppressing function adds during bioanalysis measures, and determines by measuring albumen and the interaction between its acceptor that compounds affect has cancer suppressing function whether compound is antagonist.With the same quadrat method of above-mentioned SCREENED COMPOUND, can filter out the acceptor disappearance thing and the analogue of antagonist action.

Polypeptide of the present invention can be directly used in disease treatment, for example, and various malignant tumours and cellular abnormality propagation etc.

Polypeptide of the present invention, and fragment, derivative, analogue or their cell can be used as antigen to produce antibody.These antibody can be polyclone or monoclonal antibody.Polyclonal antibody can obtain by the method with this polypeptide direct injection animal.The technology of preparation monoclonal antibody comprises hybridoma technology, three knurl technology, people B-quadroma technology, EBV-hybridoma technology etc.

Can be with polypeptide of the present invention and antagonist and suitable pharmaceutical carrier combination back use.These carriers can be water, glucose, ethanol, salt, damping fluid, glycerine and their combination.Composition comprises the polypeptide or the antagonist of safe and effective amount and carrier and the vehicle that does not influence effect of drugs.These compositions can be used as medicine and are used for disease treatment.

The present invention also provides medicine box or the test kit that contains one or more containers, and one or more medicinal compositions compositions of the present invention are housed in the container.With these containers, can have by the given indicative prompting of government authorities of making, using or selling medicine or biological products, the government authorities that this prompting reflects production, uses or sells permits it to use on human body.In addition, polypeptide of the present invention can be used in combination with other treatment compound.

Pharmaceutical composition can be with mode administration easily, as by in part, intravenously, intraperitoneal, intramuscular, subcutaneous, the nose or the route of administration of intracutaneous.Albumen with cancer suppressing function comes administration with the amount that treats and/or prevents concrete indication effectively.The proteic amount with cancer suppressing function and the dosage range that are applied to the patient will depend on many factors, as administering mode, person's to be treated healthiness condition and diagnostician's judgement.

The proteic polynucleotide of people with cancer suppressing function also can be used for multiple therapeutic purpose.Gene therapy technology can be used for treating since have that the proteic nothing of cancer suppressing function is expressed or the proteic expression with cancer suppressing function of unusual/non-activity due to cell proliferation, growth or metabolic disturbance.The albumen with cancer suppressing function that the gene therapy vector (as virus vector) of reorganization can be designed to express variation is to suppress endogenic protein-active with cancer suppressing function.For example, a kind of albumen with cancer suppressing function of variation can be the albumen with cancer suppressing function that shortens, lacked signal conduction function territory, though can combine with the substrate in downstream, lacks signaling activity.Therefore the gene therapy vector of reorganization can be used for treating the protein expression with cancer suppressing function or the disease of active caused by abnormal.Deriving from the expression vector of virus such as protein gene that retrovirus, adenovirus, adeno-associated virus (AAV), hsv, parvovirus etc. can be used for having cancer suppressing function is transferred in the cell.The method that structure carries the recombinant viral vector of the protein gene with cancer suppressing function is found in existing document (Sambrooket al.).The people protein gene of reorganization with cancer suppressing function can be packaged in the liposome and be transferred in the cell in addition.

Suppress to have cancer suppressing function people's protein mRNA oligonucleotide (comprising sense-rna and DNA) and ribozyme also within the scope of the invention.Ribozyme is the enzyme sample RNA molecule that a kind of energy specificity is decomposed specific RNA, and its mechanism of action is to carry out the endonuclease effect after ribozyme molecule and the hybridization of complementary target RNA-specific.The RNA of antisense and DNA and ribozyme can obtain with existing any RNA or DNA synthetic technology, as the technology widespread use of solid phase phosphoamide chemical synthesis synthetic oligonucleotide.Antisense rna molecule can be transcribed acquisition by the dna sequence dna of this RNA that encodes in external or body.This dna sequence dna has been incorporated into the downstream of rna polymerase promoter of carrier.In order to increase the stability of nucleic acid molecule, available several different methods is modified it, and as increasing the sequence length of both sides, the connection between the ribonucleoside is used phosphoric acid thioester bond or peptide bond but not phosphodiester bond.

Polynucleotide imports tissue or intracellular method comprises: directly be injected into polynucleotide in the in-vivo tissue; Or external by carrier (as virus, phage or plasmid etc.) earlier with the polynucleotide transfered cell in, again cell is transplanted in the body etc.

Polypeptide of the present invention also can be used as the peptide spectrum analysis, for example, the polypeptide available physical, chemistry or enzyme carry out the specificity cutting, and carry out the two-dimentional or three-dimensional gel electrophoresis analysis of one dimension.

The present invention also provides the antibody at the people's proteantigen determinant with cancer suppressing function.These antibody include, but is not limited to: the fragment that polyclonal antibody, monoclonal antibody, chimeric antibody, single-chain antibody, Fab fragment and Fab expression library produce.

The anti-proteic antibody of people with cancer suppressing function can be used in the immunohistochemistry technology, detects the people's albumen with cancer suppressing function in the biopsy specimen.

With the also available labelled with radioisotope of the protein bound monoclonal antibody of the people with cancer suppressing function, inject in the body and can follow the tracks of its position and distribution.This radiolabeled antibody can be used as a kind of atraumatic diagnostic method and is used for the location of tumour cell and has judged whether transfer.

Antibody among the present invention can be used for treating or prevents and the relevant disease of people's albumen with cancer suppressing function.The antibody that gives suitable dosage can stimulate or block proteic generation of the people with cancer suppressing function or activity.

Antibody also can be used for designing the immunotoxin at a certain privileged sites in the body.As have cancer suppressing function people's albumen high-affinity monoclonal antibody can with bacterium or plant poison (as diphtheria toxin, ricin, abrine etc.) covalent attachment.A kind of usual method is with sulfydryl linking agent such as SPDP, attacks the amino of antibody, by the exchange of disulfide linkage, toxin is incorporated on the antibody, and this hybrid antibody can be used for killing the cell of the people's protein positive with cancer suppressing function.

Available people's albumen or the polypeptide immune animal of the production of polyclonal antibody with cancer suppressing function, as rabbit, mouse, rat etc.Multiple adjuvant can be used for the enhancing immunity reaction, includes but not limited to freund's adjuvant etc.

Have cancer suppressing function people's protein monoclonal antibody can with hybridoma technology production (Kohler and Milstein.Nature, 1975,256:495-497).With the variable region bonded chimeric antibody in human constant region and inhuman source can with existing technology production (Morrison et al, PNAS, 1985,81:6851).And the technology of existing manufacture order chain antibody (U.S.PatNo.4946778) also can be used for producing the anti-proteic single-chain antibody of people with cancer suppressing function.

Can be incorporated into the rondom polypeptide storehouse that solid formation forms by the various amino acid that may make up by screening with the protein bound peptide molecule of the people with cancer suppressing function obtains.During screening, must carry out mark to people's protein molecular with cancer suppressing function.

The invention still further relates to quantitatively and detection and localization has the diagnostic testing process of people's protein level of cancer suppressing function.These tests are known in the art, and comprise that FISH measures and radioimmunoassay.The people's protein level that is detected in the test with cancer suppressing function, the disease that can have the importance of people's albumen in various diseases of cancer suppressing function with laying down a definition and be used to diagnose albumen to work with cancer suppressing function.

Proteic polynucleotide with cancer suppressing function can be used for having the diagnosis and the treatment of the protein related diseases of cancer suppressing function.Aspect diagnosis, the proteic polynucleotide with cancer suppressing function can be used for detecting have cancer suppressing function proteic expression whether or under morbid state, have an abnormal exprssion of cancer suppressing function.As the protein D NA sequence with cancer suppressing function can be used for the hybridization of biopsy specimen is had with judgement the proteic abnormal expression of cancer suppressing function.Hybridization technique comprises the Southern blotting, Northern blotting, in situ hybridization etc.These technological methods all are disclosed mature technologies, and relevant test kit all can obtain from commercial channels.Part or all of polynucleotide of the present invention can be used as probe stationary on microarray (Microarray) or DNA chip (being called " gene chip " again), is used for analyzing the differential expression analysis and the gene diagnosis of tissue gene.Carry out RNA-polymerase chain reaction (RT-PCR) amplification in vitro with the special primer of the albumen with cancer suppressing function and also can detect proteic transcription product with cancer suppressing function.

The sudden change that detection has the protein gene of cancer suppressing function also can be used for diagnosing the relevant disease of albumen with cancer suppressing function.Form with protein mutation of cancer suppressing function comprises that to have point mutation that the protein D NA sequence of cancer suppressing function compares, transposition, disappearance, reorganization and other any unusual etc. with normal wild type.Available existing technology such as Southern blotting, dna sequence analysis, PCR and in situ hybridization detect sudden change.In addition, sudden change might influence proteic expression, therefore can judge indirectly that with Northern blotting, Western blotting gene has or not sudden change.

Sequence of the present invention identifies it also is valuable to karyomit(e).This sequence can be specifically at certain bar human chromosome particular location and and can with its hybridization.At present, need to identify the concrete site of each gene on the karyomit(e).Now, have only chromosomal marker thing seldom to can be used for the marker chromosomes position based on actual sequence data (repetition polymorphism).According to the present invention, for these sequences are associated with disease related gene, its important the first step is positioned these dna sequence dnas on the karyomit(e) exactly.

In brief, prepare PCR primer (preferred 15-35bp), sequence can be positioned on the karyomit(e) according to cDNA.Then, these primers are used for the somatocyte hybrid cell that the PCR screening contains each bar human chromosome.Have only those hybrid cells that contain corresponding to the people's gene of primer can produce the fragment of amplification.

The PCR localization method of somatocyte hybrid cell is that DNA is navigated to concrete chromosomal quick method.Use Oligonucleolide primers of the present invention,, can utilize one group to realize inferior location from specific chromosomal fragment or a large amount of genomic clone by similar approach.Other the similar strategy that can be used for chromosomal localization comprises in situ hybridization, uses the karyomit(e) prescreen and the hybridization preliminary election of the airflow classification of mark, thereby makes up the special cDNA storehouse of karyomit(e).

The cDNA clone is carried out fluorescence in situ hybridization (FISH) with Metaphase Chromosome, can in a step, accurately carry out chromosomal localization.The summary of this technology is referring to Verma etc., Human Chromosomes:a Manual of BasicTechniques, Pergamon Press, New York (1988).

In case sequence is positioned to chromosome position accurately, the physical location of this sequence on karyomit(e) just can be associated with the gene map data.These data for example are found in, V.Mckusick, Mendelian Inheritance in Man (can by with the online acquisition of Johns Hopkins University Welch Medical Library).Can pass through linkage analysis then, determine gene and navigated to relation between the disease on the chromosomal region already.

Then, need to measure ill and not cDNA between diseased individuals or genome sequence difference.If observe certain sudden change in some or all of diseased individuals, and this sudden change is not observed in any normal individual, then this sudden change may be the cause of disease of disease.More ill and diseased individuals not is usually directed at first seek the variation of structure in the karyomit(e), as from the horizontal visible of karyomit(e) or use based on detectable disappearance of the PCR of cDNA sequence or transposition.Resolving power according to present physical mapping and assignment of genes gene mapping technology, being accurately positioned to the cDNA of the chromosomal region relevant with disease, can be a kind of (the supposing that 1 megabasse mapping resolving power and every 20kb are corresponding to a gene) between 50 to 500 potential Disease-causing genes.

Pyrenoids thuja acid full length sequence or its fragment with cancer suppressing function of the present invention can obtain with the method for pcr amplification method, recombination method or synthetic usually.For the pcr amplification method, can be disclosed according to the present invention about nucleotide sequence, especially open reading frame sequence designs primer, and with commercially available cDNA storehouse or by the prepared cDNA storehouse of ordinary method well known by persons skilled in the art as template, amplification and must relevant sequence.When sequence is longer, usually needs to carry out twice or pcr amplification repeatedly, and then the fragment that each time amplifies is stitched together by proper order.

In case obtained relevant sequence, just can obtain relevant sequence in large quantity with recombination method.This normally is cloned into carrier with it, changes cell again over to, separates obtaining relevant sequence then from the host cell after the propagation by ordinary method.

In addition, also the method for available synthetic is synthesized relevant sequence, especially fragment length more in short-term.Usually, by first synthetic a plurality of small segments, and then connect and to obtain the very long fragment of sequence.

At present, can be fully come the dna sequence dna of code book invention albumen (or its fragment, or derivatives thereof) by chemosynthesis.This dna sequence dna can be introduced then in the various dna moleculars (as carrier) and cell in this area.In addition, also can will suddenly change and introduce in the protein sequence of the present invention by chemosynthesis.

In addition, because the albumen with cancer suppressing function of the present invention has the natural acid sequence that is derived from the people, therefore, compare with the albumen of the same clan that derives from other species, estimate to have higher active and/or lower side effect (for example in the intravital immunogenicity of people lower or do not have) being applied to man-hour.

Below in conjunction with specific embodiment, further set forth the present invention.Should be understood that these embodiment only to be used to the present invention is described and be not used in and limit the scope of the invention.The experimental technique of unreceipted actual conditions in the following example, usually according to people such as normal condition such as Sambrook, molecular cloning: laboratory manual (New York:Cold Spring Harbor LaboratoryPress, 1989) condition described in, or the condition of advising according to manufacturer.

The acquisition of embodiment 1:cDNA gene and the restraining effect that the cancer cells clone is formed

PP7027, PP7059, PP7130, PP7298, PP7425, PP7651, PP7664, PP7827, PP7882 and PP8038 obtain by making up the human placenta cDNA library with ordinary method.Get the placenta tissue at 3,6,10 monthly ages, (GIBCO BRL company) extracts total RNA by manufacturer's specification sheets with Trizol reagent, extracts mRNA with the mRNA test kit (Pharmacia company) of purifying.Make up the cDNA library of above-mentioned mRNA with pCMV-script TMXR cDNA library construction test kit (Stratagene company).Wherein ThermoScript II is used MMLV-RT-Superscript II (GIBCO BRL) instead, and reverse transcription reaction carries out at 42 ℃.Transform XL 10-Gold recipient cell, obtained 1 * 10 ⁶The cDNA library of cfu/ μ g cDNA titre.The first round is picking cDNA clone at random, is probe with high abundance cDNA clone with the cDNA clone who has proved cancer inhibitor cell growth function thereafter, screening by hybridization cDNA library, weak positive and negative clone of picking.With Qiagen 96 orifice plate plasmid extraction test kits, carry out the extraction of plasmid DNA by shop instruction.Plasmid DNA and empty carrier transfection simultaneously hepatoma cell line 7721.After the 100ng DNA alcohol precipitation drying, add 6 μ l H ₂Transfection is treated in the O dissolving.Add 0.74 μ l liposome and 9.3 μ l serum-free mediums in every part of DNA sample, behind the mixing, room temperature was placed 10 minutes.Add 150 μ l serum-free mediums in every pipe, divide equally and add 3 holes and grow in 7721 cells of 96 orifice plates, placed 2 hours for 37 ℃, every hole adds 50 μ l serum-free mediums again, 37 ℃ 24 hours.Every hole is changed 100 μ l and is trained liquid entirely, 37 ℃ 24 hours, change the full training liquid 100 μ l that contain G418,37 ℃ 24～48 hours, the limit is observed, the training liquid that G418 concentration does not wait is changed on the limit.After about 2～3 times, there is the clone to form up to the microscopy cell, counting.Find that above clone has the cell clone of inhibition formation effect, the result is as shown in the table.

CDNA clone's transfectional cell (7721) clone formation situation

CDNA clones title	CDNA clones number (three repetitions)	Empty carrier clone number (three repetitions)
			PP7027 PP7059 PP7130 PP7298 PP7425 PP7651 PP7664 PP7827 PP7882 PP8038	?12????7?????14 ?15????18????13 ?9?????12????32 ?6?????5?????7 ?10????15????12 ?14????11????17 ?21????14????16 ?0?????0?????0 ?1?????2?????0 ?4?????7?????3	?63????58????62 ?48????38????35 ?56????50????47 ?48????38????35 ?30????32????34 ?30????32????34 ?30????32????34 ?26????29????30 ?26????29????30 ?48????38????35

Above-mentioned cDNA clone is adopted two deoxidation cessation method, on the ABI377 automatic dna sequencer, measure the nucleotide sequence of the nearly 500bp of one end.After the analysis, be defined as novel gene cloning, carry out the other end order-checking, do not obtain full length cDNA sequence yet, the design primer checks order once more, up to obtaining full length sequence (SEQ ID NO:1,4,7,10,13,16,19,22,25,28).

Embodiment 2: PCR obtains full-length gene from placenta cDNA:

Get the placenta tissue at 3,6,10 monthly ages, (GIBCO BRL company) extracts total RNA by manufacturer's specification sheets with Trizol reagent, extracts mRNA with the mRNA test kit (Pharmacia company) of purifying.With MMLV-RT-Superscript II (GIBCO BRL), ThermoScript II is carried out reverse transcription reaction at 42 ℃, obtains placenta cDNA.Utilize the different primer of commentaries on classics (as shown in the table) of each gene, by 97 ℃ of 3 minutes, 1 circulations; 94 ℃ 30 seconds → 60 ℃ 30 seconds → 72 ℃ 1 minute, totally 35 circulations; 72 ℃ 10 minutes, pcr amplification is carried out in 1 circulation, obtains to contain the amplified production of each protein gene of complete open reading frame sequence.Amplified production is through sequence verification, and the sequence that records with embodiment 1 conforms to, and changes amplified production over to host cell with routine techniques subsequently, thereby obtains recombinant protein.

Gene specific primer

Clone's title	Special primer 1 (5 ' → 3 ')	Special primer 2 (5 ' → 3 ')
			?PP7027 ?PP7059 ?PPT130 ?PP7298 ?PP7425 ?PP7651 ?PP7664 ?PP7827 ?PP7882 ?PP8038	?TGTCTTTGCACCTTGGTCCT ?CCCTCTTTGCTTGTGAGGAG ?GCTTCTGAGTAGCGTGGGAG ?TTATTCTTCGATCTTGCCCG ?TGTGTGCAGCTAATGGTCGT ?AGATTCTTCCCAGGCACAAG ?CAGGCCAGGACTAGTTCCAC ?ATGGCAACTTCTCCATCACC ?GATGGTGACAGAGGGGGAC ?CAGGTGCTTTGTGAGTGGAA	?CCTCTACAGGAGGCGTTGAG ?GGCTCTTACCTCCTGGCTTT ?TTACCAAGCACGAGTGGACA ?AGTTGCGACAGCTCAACCTT ?AATGGGCTGTGATTTGTTCC ?TTGGAATCCAGGTTGGCTAC ?CTGGCCTCAAGTGATCTTCC ?CAGCTGGGCTAGATGACCTC ?GTCACAAGTGCTCGGTCTGA ?CTCAGGCCCAGAGCTATCAG

Embodiment 3:cDNA cloned sequence is analyzed

1.PP7027

A： ( SEQ ID NO：1 ) ：2770bp 1 GTTTGAAGAC AAACTTGGAG TTCACTATAT TTAACACTTA GGACCCCTAG TATCTGCCAC 61 TGGGCTGCGG GGGCAGCTGC AGGGACACAC ACCTGTTGGG TGCCTGCTGG TTCCACCCAG121 GAGCACAGCC AGCAGCCTCA TGCCTCCTGC CCCCTGGCAG TCGGGTGCAC GTGGAGCAGG181 TGGCCTTGGC CTCGACAGGG TTCCCAGGGT CCCACTGGAA GCCCCACATG GAACTGTGCC241 TCTGGGACAT TGCTCCAGGG ACCTCGGGTG CGGGCTGGCC CCATCCTGTG GGGAGGTCCT301 GGGAGGGTCA GTCTGGCCCG CCTGCCTGCT GACTTGGGTG TGGCCTGAGC AGGTAAAGGC361 GACACAGGAG GAGAACCGGG AGCTGAGGAG CAGGTGTGAG GAGCTCCACG GGAAGAACCT421 GGAACTGGGG TAAGGAGGCC CCGTCTCCTG TCCTCCCGTC CCCATCCCCC TCGCCATCCT481 TGTCCCCATC CCCCTCGCCA TCCTTGTCCC CATCCCCCTC GCCATCCCTG TCCCCGTCCC541 CATCCCCACC TGGCCTGGGA CCGCTGGGCA CCCGAGGCAA TGGCTGTGTG TCTGTTCTCC601 TCCCACAGGA AGATCATGGA CAGGTTCGAA GAGGTTGTGT ACCAGGCCAT GGGTGAGTGC661 CCGGGCCACC GAGGCCACGT GCCTCCACGA GGGGCTGCCT ATGCCCCACC CTGGCCCTGC721 CCTGCACCCT GCCTAGGACC CCACCCTCCT GAGGCCCCTT TTCCTAACAC ACGAGTCCCT781 TCAACATGGG CCCGGCCGTG GAAGCACTGA GGCGAGTTGC GGGGAAGCTG GTGGTAGTGA 841 GGCTGGTGGC TCCCACGGAG CCAGGGCTTG GCAGGCCCCA CAGTTGTGCA GATGCTGAGC 901 TAGCAGTGGG GCTGTGGTGG GAGCAGAGTC TGTCCCGCCG TGGCCTACCC CACTCCACCC 961 TGCCCTCGCC GTGCGGCTAT GTCTAGCAGC AGCCTCTGTA GGTGTCTGGC AGGACGGGAA1021 CACCAGGCCT CATCTGGCCT CCCAAAAGCT TGGGCTCCTG GAGGTGCTAC TGTGGGGATC1081 TGTCTTAGGC TGAGTGTCAG CCGGCGGCAG GTGACCGCCT GGCCCTTGCA GTCCCTCCAG1141 GACCACCACG AAGCACGACG CACATCCTGG AGCTCGCCAT ACCGGCTCCC AGGCCTCACC1201 CTAGGCTCTA GGGTGTTGGG CGCCGCCTCT TCAGGGACCT CTGGCCCAGG CTCCAGTTCC1261 CTGCGGATCT GATGTGGAGG AAACAGCTGT TTCCTGGGCT TTGCATCCGG CCTAGAAGAT1321 CCCGGGTGGA GGGACCCATC ACCCTCCGAG GCTCACACCC ACTGCCCACC TCTCCTCCTG1381 GCGCTCGAGT CCCTTGCCTC ATTCCTTGGG CTGTCTCTGG CACCCATCGT TTCGGTTGCC1441 TCCTCATCCT GAACGTTTGC TTTTCTTTTC TCAAGAGGAA GTTCAGAAGC AGAAGGAACT1501 TTCCAAAGCT GAAATCCAGA AAGTTCTAAA AGAAAAAGAC CAACTTACCA CAGATCTGAA1561 CTCCATGGAG AAGTCCTTCT CCGACCTCTT CAAGCGTTTT GAGAAACAGA AAGAGGTGAT1621 CGAGGGCTAC CGCAAGTATG TCTCCGCCAC CCTGGTGTCC TCACCTCGGA GGCTGATGGA1681 CTCATGGTCA AGCCAGCGGA CGTAGCAACT GCTGTCTTTG CACCTTGGTC CTTGGCCAAG1741 CCTCCCCTTG CCACGGGGGC ATGGGATGAC CTGTGAACGA GACAGGGTGC AGGAGTCACA1801 GCATATGCTG GTTTGCGAGG CAGCTGAGGG CGGCAGGAGG CAGAGTGAGC AGGGAGGCCA1861 TCTGAGCCGT CCGCTGTTGT GTGACAGACG ACTCGGCTAT GATCAGGCAT CTGTGAGATT1921 TCAGACAGCG CTGGTGCACC GGGGCCTGGG GCACCTCGGA AAGGTGTCTG GGCTGTCCGA1981 GCGCTTGGGT CCCAAGGGTT GGGGACCCAG GGCATGCAGT ATCCAAGGCG GGAGGCCCAC2041 TGAAAGGTGG TCACGGCTGT GCAAGGCCAC CCTGGTGTCC TCCTGGCCAC AGGACTCTGA2101 GCGCCCCCCA CCTTCTGTGC TGGGCAAGGC CCACATGCTT GCTGGAAGGA GGGATGTCTG2161 GGCCATCCAT CTGCCCAGAG CAGGCCTGGA AGGTGCCTGC GAGGCCGCCA GAGGGTTCTG2221 CCCACAGCAG CAATGTTGGA GCGGAGGTGC TCAACGCCTC CTGTAGAGGA GCTGGACCTG2281 CAGGTGCAGC TGGAAGAGGG GCTGTCACTG TTGGTGCAAG GGGGTTGGGG ACACCAGATG2341 GGTCCCCTGG GAGTCAGACT AAACTGGAAA AGCGGCCCTT GCAGGGCCTG CTGAGCCACA2401 CCTCATCTGA GTCCTGAAGT CAGGTGGGTG TCAGTGGCTG GGGCCCAGCT GCCTAACAGA2461 AGCAAGCCTG AATACTCTAG GGAAGAAGGT ATCTTATGCT TTAAATTGCT GCTGCAGTTT2521 TAAATTAGTG TCTGGCACAG AATAACCAAG TGTGAAAGGA ACAGGAAACA TGAGTGAAAA2581 TCAGACCCGT TATTAGAGTG AGGCATGGTG ATGTACACCT GTGGTCCCAG CTACTAGGGA2641 GGCTGAGGTG GGAGGATCAT TTGAGCCCGG GAGGTTGAAG CTGCAGTGAG CCATGATTGT2701 ATCACTGCAC CCCCAGCCTG GGCAATAGAC CAAGACCCCC ATCTCTAAAA TTAAAAAAAA2761 AAAAAAAAAA

B: aminoacid sequence (SEQ ID NO:2) length: 166 amino acid/11 MTCERDRVQE SQHMLVCEAA EGGRRQSEQG GHLSRPLLCD RRLGYDQASV RFQTALVHRG 61 LGHLGKVSGL SERLGPKGWG PRACSIQGGR PTERWSRLCK ATLVSSWPQD SERPPPSVLG121 KAHMLAGRRD VWAIHLPRAG LEGACEAARG FCPQQQCWSG GAQRLL

C. Nucleotide and amino acid composite sequence (SEQ ID NO:3)

Clone number: PP7027 start code: 1766 ATG stop coding: 2264 TAG

：18244.88 1 G TTT GAA GAC AAA CTT GGA GTT CAC TAT ATT TAA CAC TTA GGA CCC 4647 CTA GTA TCT GCC ACT GGG CTG CGC GGG CAG CTG CAG GGA CAC ACA CCT 9495 GTT GGG TGC CTG CTG GTT GCA CCC AGG AGC ACA GCC AGC AGC CTC ATG 142143 CCT CCT GCC CCC TGG CAG TCG GGT GCA CGT GGA GCA GGT GGC CTT GGC 190191 CTC GAC AGG GTT GCC AGG GTC CCA CTG GAA GCC CCA CAT GGA ACT GTG 238239 CCT CTG GGA CAT TGC TCC AGG GAC CTC GGG TGC GGG CTG GCC CCA TCC 286 287 TGT GGG GAG GTC CTG GGA GGG TCA GTC TGG CCC GCC TGC CTG CTG ACT 334 335 TGG GTG TGG CCT GAG CAG GTA AAG GCG ACA CAG GAG GAG AAC CGG GAG 382 383 CTG AGG AGC AGG TGT GAG GAG CTC CAC GGG AAG AAC CTG GAA CTG GGG 430 431 TAA GGA GGC CCC GTC TCC TGT CCT CCC GTC CCC ATC CCC CTC GCC ATC 478 479 CTT GTC CCC ATC CCC CTC GCC ATC CTT GTC CCC ATC CCC CTC GCC ATC 526 527 CCT GTC CCC GTC CCC ATC CCC ACC TGG CCT GGG ACC GCT GGG CAC CCG 574 575 AGG CAA TGG CTG TGT GTC TGT TCT CCT CCC ACA GGA AGA TCA TGG ACA 622 623 GGT TCG AAG AGG TTG TGT ACC AGG CCA TGG GTG AGT GCC CGG GCC ACC 670 671 GAG GCC ACG TGC CTC CAC GAG GGG CTG CCT ATG CCC CAC CCT GGC CCT 718 719 GCC CTG CAC CCT GCC TAG GAC CCC ACC CTC CTG AGG CCC CTT TTC CTA 766 767 ACA CAC GAG TCC CTT CAA CAT GGG CCC GGC CGT GGA AGC ACT GAG GCG 814 815 AGT TGC GGG GAA GCT GGT GGT AGT GAG GCT GGT GGC TCC CAC GGA GCC 862 863 AGG GCT TGG CAG GCC CCA CAG TTG TGC AGA TGC TGA GCT AGC AGT GGG 910 911 GCT GTG GTG GGA GCA GAG TCT GTC CCG CCG TGG CCT ACC CCA CTC CAC 958 959 CCT GCC CTC GCC GTG CGG CTA TGT CTA GCA GCA GCC TCT GTA GGT GTC 10061007 TGG CAG GAC GGG AAC ACC AGG CCT CAT CTG GCC TCC CAA AAG CTT GGG 10541055 CTC CTG GAG GTG CTA CTG TGG GGA TCT GTC TTA GGC TGA GTG TCA GCC 11021103 GGC GGC AGG TGA CCG CCT GGC CCT TGC AGT CCC TCC AGG ACC ACC ACG 11501151 AAG CAC GAC GCA CAT CCT GGA GCT CGC CAT ACC GGC TCC CAG GCC TCA 11981199 CCC TAG GCT CTA GGG TGT TGG GCG CCG CCT CTT CAG GGA CCT CTG GCC 12461247 CAG GCT CCA GTT CCC TGC GGA TCT GAT GTG GAG GAA ACA GCT GTT TCC 12941295 TGG GCT TTG CAT CCG GCC TAG AAG ATC CCG GGT GGA GGG ACC CAT CAC 13421343 CCT CCG AGG CCC ACA CCC ACT GCC CAC CTC TCC TCC TGG CGC TCG AGT 13901391 CCC TTG CCT CAT TCC TTG GGC TGT CTC TGG CAC CCA TCG TTT CGG TTG 14381439 CCT CCT CAT CCT GAA CGT TTG CTT TTC TTT TCT CAA GAG GAA GTT CAG 14861487 AAG CAG AAG GAA CTT TCC AAA GCT GAA ATC CAG AAA GTT CTA AAA GAA 15341535 AAA GAC CAA CTT ACC ACA GAT CTG AAC TCC ATG GAG AAG TCC TTC TCC 15821583 GAC CTC TTC AAG CGT TTT GAG AAA CAG AAA GAG GTG ATC GAG GGC TAC 16301631 CGC AAG TAT GTC TCC GCC ACC CTG GTG TCC TCA CCT CGG AGG CTG ATG 16781679 GAC TCA TGG TCA AGC CAG CGG ACG TAG CAA CTG CTG TCT TTG CAC CTT 17261727 GGT CCT TGG CCA AGC CTC CCC TTG CCA CGG GGG CAT GGG ATG ACC TGT 1774 1 Met Thr Cys 31775 GAA CGA GAC AGG GTG CAG GAG TCA CAG CAT ATG CTG GTT TGC GAG GCA 1822 4 Glu Arg Asp Arg Val Gln Glu Ser Gln His Met Leu Val Cys Glu Ala 191823 GCT GAG GGC GGC AGG AGG CAG AGT GAG CAG GGA GGC CAT CTG AGC CGT 1870 20 Ala Glu Gly Gly Arg Arg Gln Ser Glu Gln Gly Gly His Leu Ser Arg 351871 CCG CTG TTG TGT GAC AGA CGA CTC GGC TAT GAT CAG GCA TCT GTG AGA 1918 36 Pro Leu Leu Cys Asp Arg Arg Leu Gly Tyr Asp Gln Ala Ser Val Arg 511919 TTT CAG ACA GCG CTG GTG CAC CGG GGC CTG GGG CAC CCC GGA AAG GTG 1966 52 Phe Gln Thr Ala Leu Val His Arg Gly Leu Gly His Leu Gly Lys Val 671967 TCT GGG CTG TCC GAG CGC TTG GGT CCC AAG GGT TGG GGA CCC AGG GCA 2014 68 Ser Gly Leu Ser Glu Arg Leu Gly Pro Lys Gly Trp Gly Pro Arg Ala 832015 TGC AGT ATC CAA GGC GGG AGG CCC ACT GAA AGG TGG TCA CGG CTG TGC 2062 84 Cys Ser Ile Gln Gly Gly Arg Pro Thr Glu Arg Trp Ser Arg Leu Cys 992063 AAG GCC ACC CTG GTG TCC TCC TGG CCA CAG GAC TCT GAG CGC CCC CCA 2110 100 Lys Ala Thr Leu Val Ser Ser Trp Pro Gln Asp Ser Glu Arg Pro Pro 1152111 CCT TCT GTG CTG GGC AAG GCC CAC ATG CTT GCT GGA AGG AGG GAT GTC 2158 116 Pro Ser Val Leu Gly Lys Ala His Met Leu Ala Gly Arg Arg Asp Val 1312159 TGG GCC ATC CAT CTG CCC AGA GCA GGC CTG GAA GGT GCC TGC GAG GCC 2206 132 Trp Ala Ile His Leu Pro Arg Ala Gly Leu Glu Gly Ala Cys Glu Ala 1472207 GCC AGA GGG TTC TGC CCA CAG CAG CAA TGT TGG AGC GGA GGT GCT CAA 2254 148 Ala Arg Gly Phe Cys Pro Gln Gln Gln Cys Trp Ser Gly Gly Ala Gln 1632255 CGC CTC CTG TAG AGG AGC TGG ACC TGC AGG TGC AGC TGG AAG AGG GGC 2302 164 Arg Leu Leu *** 1672303 TGT CAC TGT TGG TGC AAG GGG GTT GGG GAC ACC AGA TGG GTC CCC TGG 23502351 GAG TCA GAC TAA ACT GGA AAA GCG GCC CTT GCA GGG CCT GCT GAG CCA 23982399 CAC CTC ATC TGA GTC CTG AAG TCA GGT GGG TGT CAG TGG CTG GGG CCC 24462447 AGC TGC CTA ACA GAA GCA AGC CTG AAT ACT CTA GGG AAG AAG GTA TCT 24942495 TAT GCT TTA AAT TGC TGC TGC AGT TTT AAA TTA GTG TCT GGC ACA GAA 25422543 TAA CCA AGT GTG AAA GGA ACA GGA AAC ATG AGT GAA AAT CAG ACC CGT 25902591 TAT TAG AGT GAG GCA TGG TGA TGT ACA CCT GTG GTC CCA GCT ACT AGG 26382639 GAG GCT GAG GTG GGA GGA TCA TTT GAG CCC GGG AGG TTG AAG CTG CAG 26862687 TGA GCC ATG ATT GTA TCA CTG CAC CCC CAG CCT GGG CAA TAG ACC AAG 27342735 ACC CCC ATC TCT AAA ATT AAA AAA AAA AAA AAA AAA 2770

2.PP7059

A： ( SEQ ID NO：4 ) ：2585bp 1 PPCONGCAGC AAGGCTGATG TGGTGGACAG TGAGACTGTG GTACGGGCTC GTGGGTTGCC 61 GTGGCAGTCA TCAGACCAGG ACGTGGCTCG CTTCTTCAAA GGGCTCAACG TGGCCAGGGG 121 TGGTGTAGCA CTCTGCCTCA ACGCCCAGGG CCGCAGAAAT GGCGAGGCCC TCATCCGCTT 181 TGTGGACAGC GAGCAGCGGG ACCTAGCGCT GCAGAGACAC AAGCACCACA TGGGCGTCCG 241 CTATATTGAG GTGTATAAAG CGACAGGGGA GGAGTTTGTA AAGATTGCAG GGGGCACATC 301 ACTAGAGGTG GCTCGTTTCT TGTCACGGGA AGACCAAGTG ATCCTGCGGC TGCGGGGACT 361 GCCCTTCTCG GCTGGCCAAC GGACGTGCTT GGCTTCCTGG GGCCAGAGTG CCCAGTGACT 421 GGGGGTACCG AGGGGCTGCT CTTTGTGCGC CATCCTGATG GCCGGCCGAC TGGTGATGCC 481 TTCGCCCTCT TTGCTTGTGA GGAGCTGGCA CAGGCTGCAC TGCGCAGGCA CAAGGGCATG 541 CTGGGTAAGC GATACATTGA ACTCTTCCGG AGCACTGCAG CCGAAGTGCA GCAGGTCTTG 601 AACCGCTATG CATCCGGCCC ACTCCTTCCT ACACTGACTG CCCCACTGCT GCCCATCCCC 661 TTCCCACTGG CACCTGGGAC TGGGAGGGAC TGTGTACGCC TCCGAGGCCT GCCCTACACG 721 GCCACCATTG AAGACATCCT GAGCTTTCTG GGGGAGGCAG CAGCTGACAT TCGGCCCCAC 781 GGTGTACACA TGGTGCTCAA CCAGCAGGGC CGGCCATCGG GCGATGCCTT CATTCAGATG 841 ACATCAGCAG AGCGAGCCCT AGCTGCTGCT CAGCGTTGCC ATAAGAAGGT GATGAAGGAG 901 CGCTACGTGG AGGTGGTCCC CTGTTCCACA GAGGAGATGA GCCGAGTGCT GATGGGGGGC 961 ACCTTGGGCC GCAGTGGCAT GTCCCCTCCA CCCTGCAAGC TGCCCTGCCT CTCACCACCT1021 ACCTACACCA CCTTCCAAGC CACCCCAACG CTCATTCCCA CGGAGACGGC ACCTCTATAC1081 CCCTCTTCAG CACTGCTCCC AGCTGCCAGG GTGCCTGCTG CCCCCACCCC TGTTGCCTAC1141 TATCCAGGGC CAGCCACTCA ACTCTACCTG AACTACACAG CCTACTACCC AAGCCCCCCA1201 GTCTCCCCCA CCACTGTGGG CTACCTCACT ACACCCACTG CTGCCCTGGC CTCTGCTCCC1261 ACCTCAGTGT TGTCCCAGTC AGGAGCCTTG GTCCGCATGC AGGGTGTCCC ATACACGGCT1321 GGTATCAAGG ATCTGCTCAG CGTCTTCCAG GCCTACCAGC TACCCGCTGA TGACTACACC1381 AGTCTGATGC CTGTTGGTGA CCCACCTCGC ACTGTGTTAC AAGCCCCCAA GGAATGGGTG 1441 TGTTTGTAGG AGAGAAAGCC AGGAGGTAAG AGCCAGCTGA TATCCTCGGC GAACATGTCT 1501 CTCCTGAGTC CAGAAGACCA GCACCCTCAA CCTGGTAGCT TctttctGGC TTGTCAAAGC 1561 TCTCAGAAGG TACCTAGAGG AGCCCAAGCC CCAGCTCCAT CCTCCACTTA TTCTGCCTGT 1621 TTCCCCCAAA GACAATGGCT GGACCCTGCA TGCAGGGCTG GGGGTGGAAT GGGGCTAACC 1681 AGCTCCTGAT GGCCTGAGCC AGGCATCTTG ACTGGCACCT GGAGAGCCCT TAAGTCTGTC 1741 CTGGCTGTGG CCCATGCCGA CAGATATCGT GGGGCTGACA GGTCCACGGC AGGCTTGCTT 1801 TCTTTTATAA AATGGAAGCT CTGGTACCTT CAATGTATGA CTCCTGGGAG AATCAAGGGT 1861 CCATCTGAGC CTCTGAGTAA AGATCCCAAT GTTCTACCTC TCCCTGTCCC TCTTGTAGGG 1921 GATAGGGAGG CAGAGAGAGC CAGCCCCTAC CCTCAGAGTA TCTGGACCTC AGAGACCATG 1981 TTGTGCCAGG GGTGGTCCCA CCTAAAGATG CTAGCCCCTC TCCAGGTGGG CATAAGGAGT 2041 AACAGATGGC AAAACCACAA ACTATTTTGA TGGACTGTGC TGCAGTATCA CCAGAAGACA 2101 TTAGGGGGCA GTAGGCCCCC ACACAAAACC TTCAGGCTTG AATTTTAAAG GGGAGGACTT 2161 TCTGCCAACT TTTCTTGTAT GCCTTGGGAA AGCCAGTTGC CCTGAACCCA GCAGACACCA 2221 TGGAATGTCC TTTGCACGCA TTAAATGGTA CAGAACTGAA GCCTCGGAAG CAATTTGGAA 2281 CTCGATCTTC TCTTCCTTAA ATGAAAAGTT ATTGACCAAA TGGACTTTTT AAAAGACACA 2341 GGACCCTTAA CTTTGCCCCA AAGTGAGGGG CTCCACACCA ACCCCAGGCG GAGGAACACT 2401 CAGACAGATT AAGGATACTG TTGACCTGTC ACTGTTTATT ATTTCAGCAC TAAAACTGAG 2461 GAGCCTCAAC TGCTGGCTCT TCTTCCCTTT GTATTTGTGT AAGGAGCACT GCACTCCCAT 2521 AAAAGGTTTT AAAATACAAA ATGTACAAGA CCTCTCAAAA AAAAAAAAAA AAAAAAAAAA 2581 AAAAA

B: amino acid sequence (SEQ ID NO:5) length: 303 amino acid/11 MLGKRYIELF RSTAAEVQQV LNRYASGPLL PTLTAPLLPI PFPLAPGTGR DCVRLRGLPY 61 TATIEDILSF LGEAAADIRP HGVHMVLNQQ GRPSGDAFIQ MTSAERALAA AQRCHKKVMK121 ERYVEVVPCS TEEMSRVLMG GTLGRSGMSP PPCKLPCLSP PTYTTFQATP TLIPTETAAL181 YPSSALLPAA RVPAAPTPVA YYPGPATQLY LNYTAYYPSP PVSPTTVGYL TTPTAALASA241 PTSVLSQSGA LVRMQGVPYT AGMKDLLSVF QAYQLPADDY TSLMPVGDPP RTVLQAPKEW301 VCL

C. Nucleotide and amino acid composite sequence (SEQ ID NO:6)

Clone number: PP7059

Start code: 533 ATG stop coding: 1442 TAG

：32452.84 1 G CAG CAA GGC TGA TGT GGT GGA CAG TGA GAC TGT GGT ACG GGC TCG 46 47 TGG GTT GCC GTG GCA GTC ATC AGA CCA GGA CGT GGC TCG CTT CTT CAA 94 95 AGG GCT CAA CGT GGC CAG GGG TGG TGT AGC ACT CTG CCT CAA CGC CCA 142143 GGG CCG CAG AAA TGG CGA GGC CCT CAT CCG CTT TGT GGA CAG CGA GCA 190191 GCG GGA CCT AGC GCT GCA GAG ACA CAA GCA CCA CAT GGG CGT CCG CTA 238239 TAT TGA GGT GTA TAA AGC GAC AGG GGA GGA GTT TGT AAA GAT TGC AGG 286287 GGG CAC ATC ACT AGA GGT GGC TCG TTT CTT GTC ACG GGA AGA CCA AGT 334335 GAT CCT GCG GCT GCG GGG ACT GCC CTT CTC GGC TGG CCA ACG GAC GTG 382383 CTT GGC TTC CTC GGG CCA GAG TGC CCA GTG ACT GGG GGT ACC GAG GGG 430431 CTG CTC TTT GTG CGC CAT CCT GAT GGC CGG CCG ACT GGT GAT GCC TTC 478479 GCC CTC TTT GCT TGT GAG GAG CTG GCA CAG GCT GCA CTG CGC AGG CAC 526527 AAG GGC ATG CTG GGT AAG CGA TAC ATT GAA CTC TTC CGG AGC ACT GCA 574 1 Met Leu Gly Lys Arg Tyr Ile Glu Leu Phe Arg Ser Thr Ala 14575 GCC GAA GTG CAG CAG GTC TTG AAC CGC TAT GCA TCC GGC CCA CTC CTT 622 15 Ala Glu Val Gln Gln Val Leu Asn Arg Tyr Ala Ser Gly Pro Leu Leu 30 623 CCT ACA CTG ACT GCC CCA CTG CTG CCC ATC CCC TTC CCA CTG GCA CCT 670 31 Pro Thr Leu Thr Ala Pro Leu Leu Pro Ile Pro Phe Pro Leu Ala Pro 46 671 GGG ACT GGG AGG GAC TGT GTA CGC CTC CGA GGC CTG CCC TAC ACG GCC 718 47 Gly Thr Gly Arg Asp Cys Val Arg Leu Arg Gly Leu Pro Tyr Thr Ala 62 719 ACC ATT GAA GAC ATC CTG AGC TTT CTG GGG GAG GCA GCA GCT GAC ATT 766 63 Thr Ile Glu Asp Ile Leu Ser Phe Leu Gly Glu Ala Ala Ala Asp Ile 78 767 CGG CCC CAC GGT GTA CAC ATG GTG CTC AAC CAG CAG GGC CGG CCA TCG 814 79 Arg Pro His Gly Val His Met Val Leu Asn Gln Gln Gly Arg Pro Ser 94 815 GGC GAT GCC TTC ATT CAG ATG ACA TCA GCA GAG CGA GCC CTA GCT GCT 862 95 Gly Asp Ala Phe Ile Gln Met Thr Ser Ala Glu Arg Ala Leu Ala Ala 110 863 GCT CAG CGT TGC CAT AAG AAG GTG ATG AAG GAG CGC TAC GTG GAG GTG 910 111 Ala Gln Arg Cys His Lys Lys Val Met Lys Glu Arg Tyr Val Glu Val 126 911 GTC CCC TGT TCC ACA GAG GAG ATG AGC CGA GTG CTG ATG GGG GGC ACC 958 127 Val Pro Cys Ser Thr Glu Glu Met Ser Arg Val Leu Met Gly Gly Thr 142 959 TTG GGC CGC AGT GGC ATG TCC CCT CCA CCC TGC AAG CTG CCC TGC CTC 1006 143 Leu Gly Arg Ser Gly Met Ser Pro Pro Pro Cys Lys Leu Pro Cys Leu 1581007 TCA CCA CCT ACC TAC ACC ACC TTC CAA GCC ACC CCA ACG CTC ATT CCC 1054 159 Ser Pro Pro Thr Tyr Thr Thr Phe Gln Ala Thr Pro Thr Leu Ile Pro 1741055 ACG GAG ACG GCA GCT CTA TAC CCC TCT TCA GCA CTG CTC CCA GCT GCC 1102 175 Thr Glu Thr Ala Ala Leu Tyr Pro Ser Ser Ala Leu Leu Pro Ala Ala 1901103 AGG GTG CCT GCT GCC CCC ACC CCT GTT GCC TAC TAT CCA GGG CCA GCC 1150 191 Arg Val Pro Ala Ala Pro Thr Pro Val Ala Tyr Tyr Pro Gly Pro Ala 2061151 ACT CAA CTC TAC CTG AAC TAC ACA GCC TAC TAC CCA AGC CCC CCA GTC 1198 207 Thr Gln Leu Tyr Leu Asn Tyr Thr Ala Tyr Tyr Pro Ser Pro Pro Val 2221199 TCC CCC ACC ACT GTG GGC TAC CTC ACT ACA CCC ACT GCT GCC CTG GCC 1246 223 Ser Pro Thr Thr Val Gly Tyr Leu Thr Thr Pro Thr Ala Ala Leu Ala 2381247 TCT GCT CCC ACC TCA GTG TTG TCC CAG TCA GGA GCC TTG GTC CGC ATG 1294 239 Ser Ala Pro Thr Ser Val Leu Ser Gln Ser Gly Ala Leu Val Arg Met 2541295 CAG GGT GTC CCA TAC ACG GCT GGT ATG AAG GAT CTG CTC AGC GTC TTC 1342 255 Gln Gly Val Pro Tyr Thr Ala Gly Met Lys Asp Leu Leu Ser Val Phe 2701343 CAG GCC TAC CAG CTA CCC GCT GAT GAC TAC ACC AGT CTG ATG CCT GTT 1390 271 Gln Ala Tyr Gln Leu Pro Ala Asp Asp Tyr Thr Ser Leu Met Pro Val 2861391 GGT GAC CCA CCT CGC ACT GTG TTA CAA GCC CCC AAG GAA TGG GTG TGT 1438 287 Gly Asp Pro Pro Arg Thr Val Leu Gln Ala Pro Lys Glu Trp Val Cys 3021439 TTG TAG GAG AGA AAG CCA GGA GGT AAG AGC CAG CTG ATA TCC TCG GCG 1486 303 Leu *** 3041487 AAC ATG TCT CTC CTG AGT CCA GAA GAC CAG CAC CCT CAA CCT GGT AGC 15341535 TTC TTT CTG GCT TGT CAA AGC TCT CAG AAG GTA CCT AGA GGA GCC CAA 15821583 GCC CCA GCT CCA TCC TCC ACT TAT TCT GCC TGT TTC CCC CAA AGA CAA 16301631 TGG CTG GAC CCT GCA TGC AGG GCT GGG GGT GGA ATG GGG CTA ACC AGC 16781679 TCC TGA TGG CCT GAG CCA GGC ATC TTG ACT GGC ACC TGG AGA GCC CTT 17261727 AAG TCT GTC CTG GCT GTG GCC CAT GCC GAC AGA TAT CGT GGG GCT GAC 17741775 AGG TCC ACG GCA GGC TTG CTT TCT TTT ATA AAA TGG AAG CTC TGG TAC 18221823 CTT CAA TGT ATG ACT CCT GGG AGA ATC AAG GGT CCA TCT GAG CCT CTG 18701871 AGT AAA GAT CCC AAT GTT CTA CCT CTC CCT GTC CCT CTT GTA GGG GAT 19181919 AGG GAG GCA GAG AGA GCC AGC CCC TAC CCT CAG AGT ATC TGG ACC TCA 19661967 GAG ACC ATG TTG TGC CAG GGG TGG TCC CAC CTA AAG ATG CTA GCC CCT 20142015 CTC CAG GTG GGC ATA AGG AGT AAC AGA TGG CAA AAC CAC AAA CTA TTT 20622063 TGA TGG ACT GTG CTG CAG TAT CAC CAG AAG ACA TTA GGG GGC AGT AGG 21102111 CCC CCA CAC AAA ACC TTC AGG CTT GAA TTT TAA AGG GGA GGA CTT TCT 21582159 GCC AAC TTT TCT TGT ATG CCT TGG GAA AGC CAG TTG CCC TGA ACC CAG 22062207 CAG ACA CCA TGG AAT GTC CTT TGC ACG CAT TAA ATG GTA CAG AAC TGA 22542255 AGC CTC GGA AGC AAT TTG GAA CTC GAT CTT CTC TTC CTT AAA TGA AAA 23022303 GTT ATT GAC CAA ATG GAC TTT TTA AAA GAC ACA GGA CCC TTA ACT TTG 23502351 CCC CAA AGT GAG GGG CTC CAC ACC AAC CCC AGG CGG AGG AAC ACT CAG 23982399 ACA GAT TAA GGA TAC TGT TGA CCT GTC ACT GTT TAT TAT TTC AGC ACT 24462447 AAA ACT GAG GAG CCT CAA CTG CTG GCT CTT CTT CCC TTT GTA TTT GTG 24942495 TAA GGA GCA CTG CAC TCC CAT AAA AGG TTT TAA AAT ACA AAA TGT ACA 25422543 AGA CCT CTC AAA AAA AAA AAA AAA AAA AAA AAA AAA AA 2580

3.PP7130

A： ( SEQ ID NO：7 ) ：2247bp 1 GTGCATGTGG GGGTTGTGTG TTTAGGGGGG ATCTGTGTCT GCGCTGCGGA GCAAGAGCAA 61 GAGCTAAGGC GATGGCTGAC ATGGCTCTGG GCTTTCCCTA CTCTCAGAAG TACTTGTTGC 121 ATTCCATCTT CGCCAGCGGC CTGGTGAAGT CAGCACTGCT TTTCTCCCCA TTTTGCAGAT 181 GAGATCGTGG GGCTCACCAG CGTCCCCCAT GGCTTCTGAG TAGCGTGGGA GTGGAGTCAG 241 CACCAAGCCA GGCTCCCCGC GCCTGCCTTG CCCTCACCTG CTCCTGCTCT CTGCCAGAGG 301 CAGCATGGTC CGCAGGGCAC CATGGGGCCC GACAGAGTGA CAGCACGAGA ACTGTGCGAG 361 AACGACGACC TGGCCACCAG CCTCGTCCTG GACCCCTACC TCGGTTTCCG CACCCATAAG 421 ATGAACGTCA GCCCTGTGCC CCCCCTGCGG CGACAGCAGC ACCTGCGCTC AGCGCTGGAA 481 ACTTTCCTGA GGCAGCGGGA CCTGGAGGCT GCGTACCGGG CCCTGACGCT GGGAGGCTGG 541 ACGGCCCGCT ACTTCCAGAG CCGGGGCCCG CGGCAGGAGG CTGCCCTCAA GACCCACGTC 601 TATCGCTACC TCCGTGCCTT CCTGCCGGAA AGTGGCTTTA CCATCCTGCC CTGCACGCGC 661 TACTCCATGG AGACCAACGG GGCCAAGATC GTGTCCACTC GTGCTTGGTA AGAGGGCAGG 721 ACTCCCTGCA GGTATCCTTG GAGGAGACAG AGCTCAGAGG GGACAAGAGA GACCCTCTGT 781 TCATGGACTG GCCAACCGGG GAAAAGCGAG GGGCCTGGTC TCCGGGCATC CTAGGAAGGT 841 GGTGGGGCTA ATCCCGGAAG ACCTTTGTGG CTACCATGGT GCCGCTGGAG CAGGAGACCC 901 CGGATGTGAC CCCAGGGTTC CTGGGGCTTC CAGGAAAGAA CTAGGCTTCT GGTCAGGGCC 961 GTGCTGTCCT TACCTCCTTG TGACCTGAGC CCCCACCACA TGTTAAACAC CCCTGAGTGC1021 AATGAGGAGC CCCTGCCCCT GCCCCTGCCC CTGCCCCTGC GGGGTTCACA GTCTGGTGAG1081 GAGGTGGGGG GCAGACAAGT CAACATGCAG TCACTGGTCC CAGCTGGTAC ATGCTGCAGG1141 GGAGCTGTGA GGAATGAGCA AGTGCTCCCA GGGCGAGGCT CACACTGACA GGGGAAGCAC1201 CCGCCTGAGG GTCTGGTGGG GCGAGTAGGG GGTAGTCCAG GCAGGAGGGA TTTGGGGGCA1261 GGAGGTGCTA TGAGAGCGAG GGGAGAGAAT GGGGGCTGTA TCTGCTGTGT GCGTGCTGCC1321 CTGAAGGCTT TCAGTAGAAG GGTCCTGTGG GGCTGTGGGC TGGAGCAGGG AAGCCCACCC1381 AGGCAGGAGG GGAAGAGGGA GATCTGGAAG ATGGATCGCC AATAGCCAGC ACCAGCGCCC1441 AGGAGTCCCT CCTTCCTGGG TGCCTCTGTG CCGGAGGCCC GAGTCCCCTG AACACCTGCA1501 GGAGGCCAGG CATCGCCCAC AGCCCTGCCC CCTGGCCTCT TGGCAGGAAA AAGAATGAGA1561 AGCTGGAGCT GCTGGTGGGC TGCATTGCAG AGCTGCGGGA GGCAGATGAG GGGCTGCTGA1621 GGGCCGGTGA GAATGACTTC AGCATCATGT ACTCAACCCG CAAGCGGAGT GCTCAGCTGT1681 GGCTGGGCCC AGCCGCCTTC ATCAACCATG GTGAGGGTCA GGCAGGTGGA TGGGCAGGAC1741 GGGATAGAGC CAGGCAGGGC TGGAGGGGTG TAGTGGGAGG GTTCTGCGAC TGAGCTGCCG1801 AGCTCATCTA CCTCTCTTCT CTCTCCTGCC CCAACTGGCT CCAGACTGCA AACCCAACTG1861 CAAGGTAAGG CCTTGGGACT CGGGAGGAGA GGGCACGCAG GAAGAAAGGG TGCCTGTGGC1921 CTGGGGAAAG GGTTTTTGGT CAGTAAAGAG CCAAACACCG GCCGGGCGCG GTGGCTCATG1981 CCTGTAATCC CAGCACTTTG GGAGGCCGAG GTGGGCAGAT CACGAGGTCA GGAGATGGAG2041 ACCACGGTGA AACCCCATCT CTACTAAAAA CACAAAAAAT TAGTCGGGCG TGGTGGCGGG2101 CGCCTGTAGT CTCAGCTACT TGGGAGGCTG AGGCAGGAGA ATGGTGTGAA CCCGGGAGGC2161 GGAGCTTGCG GTGAGCCGAG ATCGCGCCAC TGCACTCCAG CCTGGGCCAC AGAGCGAGAC2221 TCTGTCTCAA AAAAAAAAAA AAAAAAA

B: aminoacid sequence (SEQ ID NO:8) length: 129 amino acid/11 MGPDRVTARE LCENDDLATS LVLDPYLGFR THKMNVSPVP PLRRQQHLRS ALETFLRQRD 61 LEAAYRALTL GGWTARYFQS RGPRQEAALK THVYRYLRAF LPESGFTILP CTRYSMETNG121 AKIVSTRAW

C. Nucleotide and amino acid composite sequence (SEQ ID NO:9)

Clone number: PP7130

Start code: 322 ATG stop coding: 709 TAA

：14844.21 1 GTG CAT GTG GGG GTT GTG TGT TTA GGG GGG ATC TGT GTC TGC GCT GCG 48 49 GAG CAA GAG CAA GAG CTA AGG CGA TGG CTG ACA TGG CTC TGG GCT TTC 96 97 CCT ACT CTC AGA AGT ACT TGT TGC ATT CCA TCT TCG CCA GCG GCC TGG 144145 TGA AGT CAG CAC TGC TTT TCT CCC CAT TTT GCA GAT GAG ATC GTG CGG 192193 CTC ACC AGC GTC CCC CAT GGC TTC TGA GTA GCG TGG GAG TGG AGT CAG 240241 CAC CAA GCC AGG CTC CCC GCG CCT GCC TTG CCC TCA CCT GCT CCT GCT 288289 CTC TGC CAG AGG CAG CAT GGT CCG CAG GGC ACC ATG GGG CCC GAC AGA 336 1 Met Gly Pro Asp Arg 5337 GTG ACA GCA CGA GAA CTG TGC GAG AAC GAC GAC CTG GCC ACC AGC CTC 384 6 Val Thr Ala Arg Glu Leu Cys Glu Asn Asp Asp Leu Ala Thr Ser Leu 21385 GTC CTG GAC CCC TAC CTC GGT TTC CGC ACC CAT AAG ATG AAC GTC AGC 432 22 Val Leu Asp Pro Tyr Leu Gly Phe Arg Thr His Lys Met Asn Val Ser 37433 CCT GTG CCC CCC CTG CGG CGA CAG CAG CAC CTG CGC TCA GCG CTG GAA 480 38 Pro Val Pro Pro Leu Arg Arg Gln Gln His Leu Arg Ser Ala Leu Glu 53481 ACT TTC CTG AGG CAG CGG GAC CTG GAG GCT GCG TAC CGG GCC CTG ACG 528 54 Thr Phe Leu Arg Gln Arg Asp Leu Glu Ala Ala Tyr Arg Ala Leu Thr 69529 CTG GGA GGC TGG ACG GCC CGC TAC TTC CAG AGC CGG GGC CCG CGG CAG 576 70 Leu Gly Gly Trp Thr Ala Arg Tyr Phe Gln Ser Arg Gly Pro Arg Gln 85577 GAG GCT GCC CTC AAG ACC CAC GTC TAT CGC TAC CTC CGT GCC TTC CTG 624 86 Glu Ala Ala Leu Lys Thr His Val Tyr Arg Tyr Leu Arg Ala Phe Leu 101 625 CCG GAA AGT GGC TTT ACC ATC CTG CCC TGC ACG CGC TAC TCC ATG GAG 672 102 Pro Glu Ser Gly Phe Thr Ile Leu Pro Cys Thr Arg Tyr Ser Met Glu 117 673 ACC AAC GGG GCC AAG ATC GTG TCC ACT CGT GCT TGG TAA GAG GGC AGG 720 118 Thr Asn Gly Ala Lys Ile Val Ser Thr Arg Ala Trp *** 130 721 ACT CCC TGC AGG TAT CCT TGG AGG AGA CAG AGC TCA GAG GGG ACA AGA 768 769 GAG ACC CTC TGT TCA TGG ACT GGC CAA CCG GGG AAA AGC GAG GGG CCT 816 817 GGT CTC CGG GCA TCC TAG GAA GGT GGT GGG GCT AAT CCC GGA AGA CCT 864 865 TTG TGG CTA CCA TGG TGC CGC TGG AGC AGG AGA CCC CGG ATG TGA CCC 912 913 CAG GGT TCC TGG GGC TTC CAG GAA AGA ACT AGG CTT CTG GTC AGG GCC 960 961 GTG CTG TCC TTA CCT CCT TGT GAC CTG AGC CCC CAC CAC ATG TTA AAC 10081009 ACC CCT GAG TGC AAT GAG GAG CCC CTG CCC CTG CCC CTG CCC CTG CCC 10561057 CTG CGG GGT TCA CAG TCT GGT GAG GAG GTG GGG GGC AGA CAA GTC AAC 11041105 ATG CAG TCA CTG GTC CCA GCT GGT ACA TGC TGC AGG GGA GCT GTG AGG 11521153 AAT GAG CAA GTG CTC CCA GGG CGA GGC TCA CAC TGA CAG GGG AAG CAC 12001201 CCG CCT GAG GGT CTG GTG GGG CGA GTA GGG GGT AGT CCA GGC AGG AGG 12481249 GAT TTG GGG GGA GGA GGT GCT ATG AGA GCG AGG GGA GAG AAT GGG GGC 12961297 TGT ATC TGG TGT GTG CGT GCT GCC CTG AAG GCT TTC AGT AGA AGG GTC 13441345 CTG TGG GGC TGT GGG CTG GAG CAG GGA AGC CCA CCC AGG CAG GAG GGG 13921393 AAG AGG GAG ATC TGG AAG ATG GAT CGC CAA TAG CCA GCA CCA GCG CCC 14401441 AGG AGT CCC TCC TTC CTG GGT GCC TCT GTG CCG GAG GCC GGA GTC CCC 14881489 TGA ACA CCT GCA GGA GGC CAG GCA TCG CCC ACA GCC CTG CCC CCT GGC 15361537 CTC TTG GCA GGA AAA AGA ATG AGA AGC TGG AGC TGC TGG TGG GCT GCA 15841585 TTG CAG AGC TGC GGG AGG CAG ATG AGG GGC TGC TGA GGG CCG GTG AGA 16321633 ATG ACT TCA GCA TCA TGT ACT CAA CCC GCA AGC GGA GTG CTC AGC TGT 16801681 GGC TGG GCC CAG CCG CCT TCA TCA ACC ATG GTG AGG GTC AGG CAG GTG 17281729 GAT GGG CAG GAC GGG ATA GAG CCA GGC AGG GCT GGA GGG GTG TAG TGG 17761777 GAG GGT TCT GCG ACT GAG CTG CCG AGC TCA TCT ACC TCT CTT CTC TCT 18241825 CCT GCC CCA ACT GGC TCC AGA CTG CAA ACC CAA CTG CAA GGT AAG GCC 18721873 TTG GGA CTC GGG AGG AGA GGG CAC GCA GGA AGA AAG GGT GCC TGT GGC 19201921 CTG GGG AAA GGG TTT TTG GTC AGT AAA GAG CCA AAC ACC GGC CGG GCG 19681969 CGG TGG CTC ATG CCT GTA ATC CCA GCA CTT TGG GAG GCC GAG GTG GGC 20162017 AGA TCA CGA GGT CAG GAG ATG GAG ACC ACG GTG AAA CCC CAT CTC TAC 20642065 TAA AAA CAC AAA AAA TTA GTC GGG CGT GGT GGC GGG CGC CTG TAG TCT 21122113 CAG CTA CTT GGG AGG CTG AGG CAG GAG AAT GGT GTG AAC CCG GGA GGC 21602161 GGA GCT TGC GGT GAG CCG AGA TCG GGC CAC TGC ACT CCA GCC TGG GCC 22082209 ACA GAG CGA GAC TCT GTC TCA AAA AAA AAA AAA AAA AAA 2247

4.PP7298

A： ( SEQ ID NO：10 ) ：2310bp 1 GGCACGGATG GAGCTCACAG TCTAGTGAGA GGTCATGGGC AATAAGTGCA TAAGCTAATT 61 TCCAGATGGT GATAAATGTG GTGGGGGAAA AATACAGGGT ACTGCTATAG AGAATGATTG121 TAAGTGAGGG TGGGGTTATT CTTGATTGGG TGGTGAGTGT GTGGGAGGAA TATTTTAAGC181 AGAAAGAATG GCTCAGGCAC AAAATGGAAA TAAGTTTGAA ATGTTGAAGG ACAGAAGGCC241 AGTGTGGCTG AAGCATTTAG GAAGGTATTA TATAGTCTAA AGGAGTTGGT GGTTTGGTCT301 AGAATGGTGG TAATTCTGTG TGCGCGCGTG TCTCCCCCGC ACCAACCTTT TTTGCACACT361 CGAAGCTGAA TATTTTCTTT TTTAGAGAAT TTACCCGCAC CTCCTGCGGG GTTCCTAAGC421 ACTCTCTCTG CTCCCCTCCC CCCAACTCCC TACCACAGGG CCGCTCCCAG TAGTTTTATT 481 CTTCGATCTT GCCCGGGCCG AGCCTGGCAG GGGCCGGTGG CTCAGCGGGC CTCGCACCCG 541 GCGCTCCGGC GCCGCCGCCG CCCAGCTGCG CCGGGGCGCC CTCCGGAGAT GCTGCCGTGG 601 AAGAAGCACA AGTTCGAGCT GCTGGCCGAG GCGCCGCCGC GGCAGGCGTC CAAGCCCAAG 661 GGCTACGCTG TGAGCCTGCA CTACTCGGCG CTCAGCTCGC TGGCGCGGGC GTGCCCCGAA 721 GGCGCGCTTA GCCGGGTGGG CAGCATGTTC CGCTCCAAGC GCAAGAAGCT GCACATCACT 781 AGCGAGGACC CAACTTACAC CGTGCTCTAC CTGGGCAATG CCACCACCAT CCAGGCGCGC 841 GGCGACGGCT GCACCGACCT TGCTGTGGGC AAGATCTGGA GCAAGAGCGA GGCGGGCCGT 901 CAGGGCACCA AGATGAAGCT GACGGTGAGT GCGCAGGGTA TCCGCATGGT GCACGCCGAG 961 GAGCGCGCGC TGCGCCGCCC GGGCCACCTC TACCTGCTGC ACCGCGTCAC CTACTGCGTG1021 GCCGACGCGC GGCTGCCCAA GGTCTTCGCC TGGGTGTACC GGCACGAGCT GAAGCACAAG1081 GCCGTGATGC TGCGCTGCCA CGCCGTGCTG GTGTCCAAGC CCGAAAAGGC GCAGGCCATG1141 GCCCTGCTGC TCTACCAGAC GTCGGCCAAC GCGCTGGCGG AATTTAAACG CCTCAAGCGG1201 CGGGACGACG CGCGTCACCA GCAGCAGGAG CTGGTGGGCG CACACACCAT CCCGCTAGTG1261 CCGCTGCGCA AGCTGCTCCT ACACGGACCC TGCTGCTATA AACCGCCGGT GGAGCGCAGC1321 CGCAAGCGCG CCCAAGCTTG GCTCCATCAC CGAGGACCTG CTCGGCGAAC AGCTGGAGCA1381 GGAGCTGCAG GAGGAAGAGG AAGAGGAGCA ACCCGAGGGC TGCCCGGAGG AGGAGGAGAA1441 CCGTGCGGCA GAGGGAGATC CAGCAGAGGA GGAGGCCGAG GCGCAGCGTG CGCTAGTGGT1501 CGCCATGCAC TTTGAGTGCG GGGACTTGTT GGATACTCTG GAGAATGGCC GTGGGGAGGC1561 GCTAGGAGGC GGCGGGGGCT CCCTGGGCCC GGGGGCCGGG CCGCCGCCTC TGCTGCTGGG1621 CAGCGCCTCC GACATGAAGG TTGAGCTGTC GCAACTTATT AGCGACCTGG GCGAGCTCAG1681 CTTCGGCAAC GACGTGCGCA CCCTGCAGGC CGACTTGCGG GTGACGCGCC TGCTGTCAGG1741 CGACAGCACG GGCAGCGAGA GCTCCATCGA GGGCGGGGGC CCTGACGCCA CTTCCGCCAC1801 CGCCGGGGAC TCGTCCCGCC AGGCCGACGG CGCCAGTGCA GACGAGCCCC ACTCGGGCTG1861 AGCTCCTCCG CGCGTCGCCG GCGCTCCACC GTGGCTACCC ATCCGTGGTC CCGACAACCT1921 CCCTGTCCCT TGCCCGCCCC CAGGAAGGGG GAAATGGGGC ATTTGGGGCC CAGACCTACA1981 CTTGGAGCCC AGGTCCAGCG TTCCCCCGAC CGCTTTCCCC TACCTCCCGG CCCCCGCTCC2041 CGCCCCAGCA CTTTTGGCTC TGTTGCGCGT GGGGATGCGG GGAGATTTGA GAGGGGAAAA2101 CCCCGCCAGG AGGGAGAGAG AGGCACCCCT CTGGGATGCG GGTGAGGGAA GGTTGGCTGA2161 AGTTCCTAGT CTCAGGCCGT AGGTGCCTGG CCAGTTTCCT GTTTGTGGGG CAGCTGGGGC2221 CTGAGGAGGA GGGGTTCACT TCCTCCTCCC ACCCCCTGGG AGCGGCCCTG CGCTGTCACT2281 GACATCTCAT TAAAAAAAAA AAAAAAAAAA

B: amino acid sequence (SEQ ID NO:11) length: 308 amino acid/11 MLPWKKHKFE LLAEAPPRQA SKPKGYAVSL HYSALSSLAR ACPEGALSRV GSMFRSKRKK 61 LHITSEDPTY TVLYLGNATT IQARGDGCTD LAVGKIWSKS EAGRQGTKMK LTVSAQGIRM121 VHAEERALRR PGHLYLLHRV TYCVADARLP KVFAWVYRHE LKHKAVMLRC HAVLVSKPEK181 AQAMALLLYQ TSANALAEFK RLKRRDDARH QQQELVGAHT IPLVPLRKLL LHGPCCYKPP241 VERSRKRAQA WLHHRGPARR TAGAGAAGGR GRGATRGLPG GGGEPCGRGR SSRGGGRGAA301 CASGRHAL

C. Nucleotide and amino acid composite sequence (SEQ ID NO:12)

Clone number: PP7298

Start code: 589 ATG stop coding: 1513 TGA

：33697.42 1 GGC ACG GAT GGA GCT CAC AGT CTA GTG AGA GGT CAT GGG CAA TAA GTG 48 49 CAT AAG CTA ATT TCC AGA TGG TGA TAA ATG TGG TGG GGG AAA AAT ACA 96 97 GGG TAC TGC TAT AGA GAA TGA TTG TAA GTG AGG GTG GGG TTA TTC TTG 144145 ATT GGG TGG TGA GTG TGT GGG AGG AAT ATT TTA AGC AGA AAG AAT GGC 192193 TCA GCC ACA AAA TGG AAA TAA GTT TGA AAT GTT GAA GGA CAG AAG GCC 240241 AGT GTG GCT GAA GCA TTT AGG AAG CTA TTA TAT AGT CTA AAG GAG TTG 288 289 GTG GTT TGG TCT AGA ATG GTG GTA ATT CTG TGT GCG CGC GTG TCT CCC 336 337 CCG CAC CAA CCT TTT TTG CAC ACT CGA AGC TGA ATA TTT TCT TTT TTA 384 385 GAG AAT TTA CCC GCA CCT CCT GCG GGG TTC CTA AGC ACT CTC TCT GCT 432 433 CCC CTC CCC CCA ACT CCC TAC CAC AGG GCC GCT CCC AGT AGT TTT ATT 480 481 CTT CGA TCT TGC CCG GGG CGA GCC TGG CAG GGG CCG GTG GCT CAG CGG 528 529 GCC TCG CAC CCG GCG CTC CGC CGC CGC CGC CGC CCA GCT GCG CCG GGG 576 577 CGC CCT CCG GAG ATG CTG CCG TGG AAG AAG CAC AAG TTC GAG CTG CTG 624 1 Met Leu Pro Trp Lys Lys His Lys Phe Glu Leu Leu 12 625 GCC GAG GCG CCG CCG CGG CAG GCG TCC AAG CCC AAG GGC TAC GCT GTG 672 13 Ala Glu Ala Pro Pro Arg Gln Ala Ser Lys Pro Lys Gly Tyr Ala Val 28 673 AGC CTG CAC TAC TCG GCG CTC AGC TCG CTG GCG CGG GCG TGC CCC GAA 720 29 Ser Leu His Tyr Ser Ala Leu Ser Ser Leu Ala Arg Ala Cys Pro Glu 44 721 GGC GCG CTT AGC CGG GTG GGC AGC ATG TTC CGC TCC AAG CGC AAG AAG 768 45 Gly Ala Leu Ser Arg Val Gly Ser Met Phe Arg Ser Lys Arg Lys Lys 60 769 CTG CAC ATC ACT AGC GAG GAC CCA ACT TAC ACC GTG CTC TAC CTG GGC 816 61 Leu His Ile Thr Ser Glu Asp Pro Thr Tyr Thr Val Leu Tyr Leu Gly 76 817 AAT GCC ACC ACC ATC CAG GCG CGC GCC GAC GGC TGC ACC GAC CTT GCT 864 77 Asn Ala Thr Thr Ile Gln Ala Arg Gly Asp Gly Cys Thr Asp Leu Ala 92 865 GTG GGC AAG ATC TGG AGC AAG AGC GAG GCG GGC CGT CAG GGC ACC AAG 912 93 Val Gly Lys Ile Trp Ser Lys Ser Glu Ala Gly Arg Gln Gly Thr Lys 108 913 ATG AAG CTG ACG GTG AGT GCG CAG GGT ATC CGC ATG GTG CAC GCC GAG 960 109 Met Lys Leu Thr Val Ser Ala Gln Gly Ile Arg Met Val His Ala Glu 124 961 GAG CGC GCG CTG CGC CGC CCG GGC CAC CTC TAC CTG CTG CAC CGC GTC 1008 125 Glu Arg Ala Leu Arg Arg Pro Gly His Leu Tyr Leu Leu His Arg Val 1401009 ACC TAC TGC GTG GCC GAC GCG CGG CTG CCC AAG GTC TTC GCC TGG GTG 1056 141 Thr Tyr Cys Val Ala Asp Ala Arg Leu Pro Lys Val Phe Ala Trp Val 1561057 TAC CGG CAC GAG CTG AAG CAC AAG GCC GTG ATG CTG CGC TGC CAC GCC 1104 157 Tyr Arg His Glu Leu Lys His Lys Ala Val Met Leu Arg Cys His Ala 1721105 GTG CTG GTG TCC AAG CCC GAA AAG GCG CAG GCC ATG GCC CTG CTG CTC 1152 173 Val Leu Val Ser Lys Pro Glu Lys Ala Gln Ala Met Ala Leu Leu Leu 1881153 TAC CAG ACG TCG GCC AAC GCG CTG GCG GAA TTT AAA CGC CTC AAG CGG 1200 189 Tyr Gln Thr Ser Ala Asn Ala Leu Ala Glu Phe Lys Arg Leu Lys Arg 2041201 CGG GAC GAC GCG CGT CAC CAG CAG CAG GAG CTG GTG GGC GCA CAC ACC 1248 205 Arg Asp Asp Ala Arg His Gln Gln Gln Glu Leu Val Gly Ala His Thr 2201249 ATC CCG CTA GTG CCG CTG CGC AAG CTG CTC CTA CAC GGA CCC TGC TGC 1296 221 Ile Pro Leu Val Pro Leu Arg Lys Leu Leu Leu His Gly Pro Cys Cys 2361297 TAT AAA CCG CCG GTG GAG CGC AGC CGC AAG CGC GCC CAA GCT TGG CTC 1344 237 Tyr Lys Pro Pro Val Glu Arg Ser Arg Lys Arg Ala Gln Ala Trp Leu 2521345 CAT CAC CGA GGA CCT GCT CGG CGA ACA GCT GGA GCA GGA GCT GCA GGA 1392 253 His His Arg Gly Pro Ala Arg Arg Thr Ala Gly Ala Gly Ala Ala Gly 2681393 GGA AGA GGA AGA GGA GCA ACC CGA GGG CTG CCC GGA GGA GGA GGA GAA 1440 269 Gly Arg Gly Arg Gly Ala Thr Arg Gly Leu Pro Gly Gly Gly Gly Glu 2841441 CCG TGC GGC AGA GGG AGA TCC AGC AGA GGA GGA GGC CGA GGC GCA GCG 1488 285 Pro Cys Gly Arg Gly Arg Ser Ser Arg Gly Gly Gly Arg Gly Ala Ala 3001489 TGC GCT AGT GGT CGC CAT GCA CTT TGA GTG CGG GGA CTT GTT GGA TAC 1536 301 Cys Ala Ser Gly Arg His Ala Leu *** 3091537 TCT GGA GAA TGG CCG TGG GGA GGC GCT AGG AGG CGG CGG GGG CTC CCT 15841585 GGG CCC GGG GGC CGG GCC GCC GCC TCT GCT GCT GGG CAG CGC CTC CGA 16321633 CAT GAA GGT TGA GCT GTC GCA ACT TAT TAG CGA CCT GGG CGA GCT CAG 16801681 CTT CGG CAA CGA CGT GCG CAC CCT GCA GGC CGA CTT GCG GGT GAC GCG 17281729 CCT GCT GTC AGG CGA CAG CAC GGG CAG CGA GAG CTC CAT CGA GGG CGG 17761777 GGG CCC TGA CGC CAC TTC CGC CAC CGC CGG GGA CTC GTC CCG CCA GGC 18241825 CGA CGG CGC CAG TGC AGA CGA GCC CCA CTC GGG CTG AGC TCC TCC GCG 18721873 CGT CGC CGG CGC TCC ACC GTG GCT ACC CAT CCG TGG TCC CGA CAA CCT 19201921 CCC TGT CCC TTG CCC GCC CCC AGG AAG GGG GAA ATG GGG CAT TTG GGG 19681969 CCC AGA CCT ACA CTT GGA GCC CAG GTC CAG CGT TCC CCC GAC CGC TTT 20162017 CCC CTA CCT CCC GGC CCC CGC TCC CGC CCC AGC ACT TTT GGC TCT GTT 20642065 GCG CGT GGG GAT GCG GGG AGA TTT GAG AGG GGA AAA CCC CGC CAG GAG 21122113 GGA GAG AGA GGC ACC CCT CTG GGA TGC GGG TGA GGG AAG GTT GGC TGA 21602161 AGT TCC TAG TCT CAG GCC GTA GGT GCC TGG CCA GTT TCC TGT TTG TGG 22082209 GGC AGC TGG GGC CTG AGG AGG AGG GGT TCA CTT CCT CCT CCC ACC CCC 22562257 TGG GAG CGG CCC TGC GCT GTC ACT GAC ATC TCA TTA AAA AAA AAA AAA 23042305 AAA AAA 2310

5.PP7425

A： ( SEQ ID NO：13 ) ：1954bp 1 GTGACGCCCG AGGACCCAGA GGAAACCCAG CCGCTTCTGG GGCCTCCTGG CGGCAGCGCG 61 CCCCGCGGCC GCCGCGTCTT CCTCGCCGCC TTCGCCGCTG CCCTGGGCCC ACTCAGCTTC121 GGCTTCGCGC TCGGCTACAG CTCCCCGGCC ATCCCTAGCC TGCAGCGCGC CGCGCCCCCG181 GCCCCGCGCC TGGACGACGC CGCCGCCTCC TGGTTCGGGG CTGTCGTGAC CCTGGGTGCC241 GCGGCGGGGG GAGTGCTGGG CGGCTGGCTG GTGGACCGCG CCGGGCGCAA GCTGAGCCTC301 TTGCTGTGCT CCGTGCCCTT CGTGGCCGGC TTTGCCGTCA TCACCGCGGC CCAGGACGTG361 TGGATGCTGC TGGGGGGCCG CCTCCTCACC GGCCTGGCCT GCGGTGTTGC CTCCCTAGTG421 GCCCCGGTCT ACATCTCCGA AATCGCCTAC CCAGCAGTCC CGGGGGTTGC TCGGCTCCTG481 TGTGCAGCTA ATGGTCGTCG TCGGCATCCT CCTGGCCTAC CTGGCAGGCT GGGTGCTGGA541 GTGGCGCTGG CTGGCTGTGC TGGGCTGCGT GCCCCCCTCC CTCATGCTGC TTCTCATGTG601 CTTCATGCCC GAGACCCCGC GCTTCCTGCT GACTCAGCAC AGGCGCCAGG AGGCCATGGC661 CGCCCTGCGG TTCCTGTGGG GCTCCGAGCA GGGCTGGGAA GACCCCCCCA TCGGGGCTGA721 CCAGAGCTTT CACCTGGCCC TGCTGCGGCA GCCCGGCATC TACAAGCCCT TCATCATCGG781 CGTCTCCCTG ATGGCCTTCC AGCAGCTGTC GGGGGTCAAC GCCGTCATGT TCTATGCAGA841 GACCATCTTT GAAGAGGCCA AGTTCAAGGA CAGCAGCCTG GCCTCGGTCG TCGTGGGTGT901 CATCCAGGTG CTGTTCACAG CTGTGGCGGC TCTCATCATG GACAGAGCAG GGCGGAGGCT961 GCTCCTGGTC TTGTCAGGTG TGGTCATGGT GTTCAGCACG AGTGCCTTCG GCGCCTACTT1021 CAAGCTGACC CAGGGTGGCC CTGGCAACTC CTCGCACGTG GCCATCTCGG CGCCTGTCTC1081 TGCACAGCCT GTTGATGCCA GCGTGGGGCT GGCCTGGCTG GCCGTGGGCA GCATGTGCCT1141 CTTCATCGCC GGAGGTCCTC AGGCCCTATG GAGCCTTCTG GCTTGCCTCC GCTTTCTGCA1201 TCTTCAGTGT CCTTTTCACT TTGTTCTGTG TCCCTGAAAC TAAAGGAAAG ACTCTGGAAC1261 AAATCACAGC CCATTTTGAG GGGCGATGAC AGCCACTCAC TAGGGGATGG AGCAAGCCTG1321 TGACTCCAAG CTGGGCCCAA GCCCAGAGCC CCTGCCTGCC CCAGGGGAGC CAGAATCCAG1381 CCCCTTGCAG CCTTGGTCTG CAGGGTCCCT CCTTCCTGTC ATGCTCCCTC CAGCCCATGA1441 CCCGGGGCTA GGAGGCTCAC TGCCTCCTGT TCCAGCTCCT GCTGCTGCTC TGAGGACTCA1501 GGAACACCTT CGAGCTTTGC AGACCTGCGG TCAGCCCTCC ATGCGCAAGA CTAAAGCAGC1561 GGAAGAGGAG GTGGGCCTCT AGGATCTTTG TCTTCTGGCT GGAGGTGCTT TTGGAGGTTG1621 GGTGCTGGGC ATTCAGTCGC TCCTCTCACG CGGCTGCCTT ATCGGGAAGG AAATTTGTTT1681 GCCAAATAAA GACTGACACA GAAAATCAGG TCAGTGTCTC TGGGCTTTGT GCAAGCTCAG1741 TTTGAAAAGG GTTTATTCCC ATCACTGCCC AGGACACCCT GTGGCTTTAC TTGCTCATGG1801 TCAGCCAAGC TTACCCTTCA CACTGAGAAG TCATTTCTGG CTACTTCCTT GGGCTCAGTT1861 CCCTGGGTCA TCAGCCATCA AATCTTGTTG AGTTTAAAAA ATAAACAGCA AAAAAAAACA1921 AACAAAACAA AAAAAAAAAA AAAAAAAAAA AAAA

B: amino acid sequence (SEQ ID NO:14) length: 248 amino acid/11 MVVVGILLAY LAGWVLEWRW LAVLGCVPPS LMLLLMCFMP ETPRFLLTQH RRQEAMAALR 61 FLWGSEQGWE DPPIGAEQSF HLALLRQPGI YKPFIIGVSL MAFQQLSGVN AVMFYAETIF121 EEAKFKDSSL ASVVVGVIQV LFTAVAALIM DRAGRRLLLV LSGVVMVFST SAFGAYFKLT181 QGGPGNSSHV AISAPVSAQP VDASVGLAWL AVGSMCLFIA GGPQALWSLL ACLRFLHLQC241 PFHFVLCP

C. Nucleotide and amino acid composite sequence (SEQ ID NO:15)

Clone number: PP7425

Start code: 491 ATG stop coding: 1235 TGA

：27015.64 1 G TGA CGC CCG AGG ACC CAG AGG AAA CCC AGC CGC TTC TGG GGC CTC 46 47 CTG GCG GCA GCG CGC CCC GCG GCC GCC GCG TCT TCC TCG CCG CCT TCG 94 95 CCG CTG CCC TGG GCC CAC TCA GCT TCG GCT TCG CGC TCG GCT ACA GCT 142143 CCC CGG CCA TCC CTA GCC TGC AGC GCG CCG CGC CCC CGG CCC CGC GCC 190191 TGG ACG ACG CCG CCG CCT CCT GGT TCG GGG CTG TCG TGA CCC TGG GTG 238239 CCG CGG CGG GGG GAG TGC TGG GCG GCT GGC TGG TGG ACC GCG CCG GGC 286287 GCA AGC TGA GCC TCT TGC TGT GCT CCG TGC CCT TCG TGG CCG GCT TTG 334335 CCG TCA TCA CCG CGG CCC AGG ACG TGT GGA TGC TGC TGG GGG GCC GCC 382383 TCC TCA CCG GCC TGG CCT GCG GTG TTG CCT CCC TAG TGG CCC CGG TCT 430431 ACA TCT CCG AAA TCG CCT ACC CAG CAG TCC CGG GGG TTG CTC GGC TCC 478479 TGT GTG CAG CTA ATG GTC GTC GTC GGC ATC CTC CTG GCC TAC CTG GCA 526 1 Met Val Val Val Gly Ile Leu Leu Ala Tyr Leu Ala 12527 GGC TGG GTG CTG GAG TGG CGC TGG CTG GCT GTG CTG GGC TGC GTG CCC 574 13 Gly Trp Val Leu Glu Trp Arg Trp Leu Ala Val Leu Gly Cys Val Pro 28575 CCC TCC CTC ATG CTG CTT CTC ATG TGC TTC ATG CCC GAG ACC CCG CGC 622 29 Pro Ser Leu Met Leu Leu Leu Met Cys Phe Met Pro Glu Thr Pro Arg 44623 TTC CTG CTG ACT CAG CAC AGG CGC CAG GAG GCC ATG GCC GCC CTG CGG 670 45 Phe Leu Leu Thr Gln His Arg Arg Gln Glu Ala Met Ala Ala Leu Arg 60 671 TTC CTG TGG GGC TCC GAG CAG GGC TGG GAA GAC CCC CCC ATC GGG GCT 718 61 Phe Leu Trp Gly Ser Glu Gln Gly Trp Glu Asp Pro Pro Ile Gly Ala 76 719 GAG CAG AGC TTT CAC CTG GCC CTG CTG CGG CAG CCC GGC ATC TAC AAG 766 77 Glu Gln Ser Phe His Leu Ala Leu Leu Arg Gln Pro Gly Ile Tyr Lys 92 767 CCC TTC ATC ATC GGC GTC TCC CTG ATG GCC TTC CAG CAG CTG TCG GGG 814 93 Pro Phe Ile Ile Gly Val Ser Leu Met Ala Phe Gln Gln Leu Ser Gly 108 815 GTC AAC GCC GTC ATG TTC TAT GCA GAG ACC ATC TTT GAA GAG GCC AAG 862 109 Val Asn Ala Val Met Phe Tyr Ala Glu Thr Ile Phe Glu Glu Ala Lys 124 863 TTC AAG GAC AGC AGC CTG GCC TCG GTC GTC GTG GGT GTC ATC CAG GTG 910 125 Phe Lys Asp Ser Ser Leu Ala Ser Val Val Val Gly Val Ile Gln Val 140 911 CTG TTC ACA GCT GTG GCG GCT CTC ATC ATG GAC AGA GCA GGG CGG AGG 958 141 Leu Phe Thr Ala Val Ala Ala Leu Ile Met Asp Arg Ala Gly Arg Arg 156959 CTG CTC CTG GTC TTG TCA GGT GTG GTC ATG GTG TTC AGC ACG AGT GCC 1006 157 Leu Leu Leu Val Leu Ser Gly Val Val Met Val Phe Ser Thr Ser Ala 1721007 TTC GGC GCC TAC TTC AAG CTG ACC CAG GGT GGC CCT GGC AAC TCC TCG 1054 173 Phe Gly Ala Tyr Phe Lys Leu Thr Gln Gly Gly Pro Gly Asn Ser Ser 1881055 CAC GTG GCC ATC TCG GCG CCT GTC TCT GCA CAG CCT GTT GAT GCC AGC 1102 189 His Val Ala Ile Ser Ala Pro Val Ser Ala Gln Pro Val Asp Ala Ser 2041103 GTG GGG CTG GCC TGG CTG GCC GTG GGC AGC ATG TGC CTC TTC ATC GCC 1150 205 Val Gly Leu Ala Trp Leu Ala Val Gly Ser Met Cys Leu Phe Ile Ala 2201151 GGA GGT CCT CAG GCC CTA TGG AGC CTT CTG GCT TGC CTC CGC TTT CTG 1198 221 Gly Gly Pro Gln Ala Leu Trp Ser Leu Leu Ala Cys Leu Arg Phe Leu 2361199 CAT CTT CAG TGT CCT TTT CAC TTT GTT CTG TGT CCC TGA AAC TAA AGG 1246 237 His Leu Gln Cys Pro Phe His Phe Val Leu Cys Pro *** 2491247 AAA GAC TCT GGA ACA AAT CAC AGC CCA TTT TGA GGG GCG ATG ACA GCC 12941295 ACT CAC TAG GGG ATG GAG CAA GCC TGT GAC TCC AAG CTG GGC CCA AGC 13421343 CCA GAG CCC CTG CCT GCC CCA GGG GAG CCA GAA TCC AGC CCC TTG CAG 13901391 CCT TGG TCT GCA GGG TCC CTC CTT CCT GTC ATG CTC CCT CCA GCC CAT 14381439 GAC CCG GGG CTA GGA GGC TCA CTG CCT CCT GTT CCA GCT CCT GCT GCT 14861487 GCT CTG AGG ACT CAG GAA CAC CTT CGA GCT TTG CAG ACC TGC GGT CAG 15341535 CCC TCC ATG CGC AAG ACT AAA GCA GCG GAA GAG GAG GTG GGC CTC TAG 15821583 GAT CTT TGT CTT CTG GCT GGA GGT GCT TTT GGA GGT TGG GTG CTG GGC 16301631 ATT CAG TCG CTC CTC TCA CGC GGC TGC CTT ATC GGG AAG GAA ATT TGT 16781679 TTG CCA AAT AAA GAC TGA CAC AGA AAA TCA GGT CAG TGT CTC TGG GCT 17261727 TTG TGC AAG CTC AGT TTG AAA AGG GTT TAT TCC CAT CAC TGC CCA GGA 17741775 CAC CCT GTG GCT TTA CTT GCT CAT GGT CAG CCA AGC TTA CCC TTC ACA 18221823 CTG AGA AGT CAT TTC TGG CTA CTT CCT TGG GCT CAG TTC CCT GGG TCA 18701871 TCA GCC ATC AAA TCT TGT TGA GTT TAA AAA ATA AAC AGC AAA AAA AAA 19181919 CAA ACA AAA CAA AAA AAA AAA AAA AAA AAA AAA AAA 1954

6.PP7651

A： ( SEQ ID NO：16 ) ：2463bp 1 GTTTGTCTCA CACAAGTGCA TCCCTGTCCA TTTCTAAGTG CGCCCTTGTC CTTTGGGGAG 61 TGTGGCCTGT GAAACATGGT GCATGCCTGC AGTTATGTGT GTGTTTGAAA ACACAAGATC 121 CTGCACGGGG AAGTGGTTGA GTGTGTGTTT GTGCATATGC GTGGGTGTGT CGCTGCCTTG 181 TAGGCAAGCA TGTTCACCTG TGATCGGTCT TCCTGAGTAC ATGCAGGCAT GGAGGCAAAC 241 ATGCACCTCT GCAGAAGTGT TCACATGTGA TGAAGTCCAT CCACATGTTT GCAGGGGTTT 301 GAGTGTGTCA TCCCCCAGCT AGAAGCTTGC GTTTGTGCAG TGGGACATGC ATCAGTCCTG 361 CACATATAGC CTTGGGGCTC ATTACACCAG CCAGCCTCCT CTCCCCACTT CCCCAGAAGG 421 GGAGGCCTTG CCATGCCCTG GGGGAGGAGA CGGTGGAGTC CAGAGGTTGA CCTGAAAGAG 481 TGAGATTCTT CCCAGGCACA AGCACACAGA TGGGCTCAGC CACAGTGCTC CTGGCAGGTT 541 TACAGCTGGA AAACAACACA AAAAATTTTT ATCTTGTGTT GAAAATAACT ACTACCCTGA 601 CCGTGACCCC AGGGCTTCCT CTGAGTAAGG AGAGACCTCC TAGACTCCTT AGCATCCAGA 661 TTCCCTCGCT TCCCAGAGGG CAACCCAAAA GCACAGAGCC CCAAGGCCCA GCTCCTGCCC 721 CTAAGCTCTC CTGCCCATCT CTCTCTCCCA CCCCCACTTG GTTCCACGCA TTCTTCAGCC 781 ATGACATCCT CACTCCAGGA GCTCAGCAGC CAGGGCCATG CCCTGCCCTG CCTTGCACTT 841 GCTCTGCCCT GGTTCTACAC TGGCCCTGGA CCCGCAGGCC AGCACAGTTC TGTGGCCTCT 901 GCACCAGGGT TTCACTCAAG GAGGAGTGGG GGCAGAGAGT GTGGGTGAGC CAGCGTTCCC 961 TGAGGAGGTC TAGAGCTGAC TTTGAGCTTA CGGGTTGTGT TGGGATAATA TTAAAGTGGC1021 TGGTGGGTGC GTACCGTGTT GCATGCTCTG TGCTGGGGGT TCGTGTATAT GTCTTATTTC1081 ATGCAGTAAT CCTAGGAGAC AGATTCTGTT ATGTAGGAGA ACACTGAGGC TTAGAAGAGT1141 TTACATGACT TGTCAGCTAA TAGTAGCCAA CCTGGATTCC AAGACAGGTC TGTCTGACTC1201 CAAAGACCTT GCCCTTTGCT CTATGTCCAA AGGTGAGTCT AAATGTCCAG CCACACCTGT1261 ATGCGGTGAT GCCTGTGGGT TTGGGTGTGG GAGCCTGCAG GTACAATGCC TGTGAAAGGT1321 ATAATATGTG TGTACGGGCA CAGTAGCTTA TGCCTGTAAT CCCAGCACTT TGGGAGGCCA1381 AGGCAGGAGG ATCACCTGTG GTCAGGAGTT CAAGAACAGC CTGATCAACA AGGTGAAACC1441 TCGTCTCTAC TAAAAAAAAA AATACAAAAA TTAGCTGGGC GAGGCTGAGA CAGGAGAATT1501 GCTTGAACCC AGGAGGCAGA GGTTGCAGTG AGCTGAGATT GCACCACTGC ACTCCAGCCT1561 GGGTGACAGA GTGAGACTCC ATTTCAAAAA AAAAAGAAAG AAAGGTATAA CACAAGCCTA1621 AGTGTGGAGG CATTCGTGTG GCAGATGCAC ATCTACGTGA ACTTTGGTGA GTATGAACCC1681 ACTGCTTCTT CCTTGGAGTG TACCTCCCAT CCCATGTCCT TGTTAAGGCC ACTCTGCATG1741 TCACCTGGGA AGCATCTTCT GTTGCCGTCC CATCAGTTGC TGAGCCAAGG CCACCTGCCG1801 AGGATGGCGA TTCAAGTAAG AGTAGCTTTC TCATGGGTTG GAAGAGATTT GGGGTCACTT1861 ACTGGCTGGT GACCTTGAGT GAGTTATCGC CCTTCATAGG CTCAAGTGTT CTGATGTCTA1921 AAGTCAGGGA GGTGGGCTGG AACCTAAACC TAGCCACTTA GGTTATCTCT CTCTGAGAGT1981 TTCTAATGCT CTGCAAGAGC ATGGTGTGGA GTGTGGCTTA CTGGGCATGT TGTGGGCAGG2041 CCAGGATTAA ATTAATTAAT GGGAAAGCAC TTTGCCAATT GGAAAGCACC ACAAAAATTT2101 CAACATTTAC ATAAGGTGTC ATTATCACGA CTATTATTTG CTTAATGGGT CCAGAGCTTG2161 CAGCTGGTTT GTGTATGTTG GAGCTTGTGC ATGTGTGTTT TTTAAAAACC GTGTGTGACT2221 GTGTGTGTAT TTTGTTGTGG ATGTGTCCGT CTGAGTATCT ATTTTGATAT ATGTATTTAC2281 AGTAGGGGTT CTAGAGAGTG CAAGTGGGTG CTGCACTGGG AATGGGGAAG GCCTGAGTTA2341 TACGTCCAGT TTTCCAGTGA CTAGCAATTA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA2401 AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA2461 AAA

B: amino acid sequence (SEQ ID NO:17) length: 205 amino acid/11 MGSATVLLAG LQLENNTKNF YLVLKITTTL TVTPGLPLSK ERPPRLLSIQ IPSLPRGQPK 61 STEPQGPAPA PKLSCPSLSP TPTWFHAFFS HDILTPGAQQ PGPCPALPCT CSALVLHWPW121 TRRPAQFCGL CTRVSLKEEW GQRVWVSQRS LRRSRADFEL TGCVGIILKW LVGAYRVACS181 VLGVRVYVLF HAVILGDRFC YVGEH

C. Nucleotide and amino acid composite sequence (SEQ ID NO:18)

Clone number: PP7651

Start code: 510 ATG stop coding: 1125 TGA

：22613.30 1 GT TTG TCT CAC ACA AGT GCA TCC CTG TCC ATT TCT AAG TGC GCC CTT 47 48 GTC CTT TGG GGA GTG TGG CCT GTG AAA CAT GGT GCA TGC CTG CAG TTA 95 96 TGT GTG TGT TTG AAA ACA CAA GAT CCT GCA CGG GGA AGT GGT TGA GTG 143 144 TGT GTT TGT GCA TAT GCG TGG GTG TGT CGC TGC CTT GTA GGC AAG CAT 191 192 GTT CAC CTG TGA TCG GTC TTC CTG AGT ACA TGC AGG CAT GGA GGC AAA 239 240 CAT GCA CCT CTG CAG AAG TGT TCA CAT GTG ATG AAG TCC ATC CAC ATG 287 288 TTT GCA GGG GTT TGA GTG TGT CAT CCC CCA GCT AGA AGC TTG CGT TTG 335 336 TGC AGT GGG ACA TGC ATC AGT CCT GCA CAT ATA GCC TTG GGG CTC ATT 383 384 ACA CCA GCC AGC CTC CTC TCC CCA CTT CCC CAG AAG GGG AGG CCT TGC 431 432 CAT GCC CTG GGG GAG GAG ACG GTG GAG TCC AGA GGT TGA CCT GAA AGA 479 480 GTG AGA TTC TTC CCA GGC ACA AGC ACA CAG ATG GGC TCA GCC ACA GTG 527 1 Met Gly Ser Ala Thr Val 6 528 CTC CTG GCA GGT TTA CAG CTG GAA AAC AAC ACA AAA AAT TTT TAT CTT 575 7 Leu Leu Ala Gly Leu Gln Leu Glu Asn Asn Thr Lys Asn Phe Tyr Leu 22 576 GTG TTG AAA ATA ACT ACT ACC CTG ACC GTG ACC CCA GGG CTT CCT CTG 623 23 Val Leu Lys Ile Thr Thr Thr Leu Thr Val Thr Pro Gly Leu Pro Leu 38 624 AGT AAG GAG AGA CCT CCT AGA CTC CTT AGC ATC CAG ATT CCC TCG CTT 671 39 Ser Lys Glu Arg Pro Pro Arg Leu Leu Ser Ile Gln Ile Pro Ser Leu 54 672 CCC AGA GGG CAA CCC AAA AGC ACA GAG CCC CAA GGC CCA GCT CCT GCC 719 55 Pro Arg Gly Gln Pro Lys Ser Thr Glu Pro Gln Gly Pro Ala Pro Ala 70 720 CCT AAG CTC TCC TGC CCA TCT CTC TCT CCC ACC CCC ACT TGG TTC CAC 767 71 Pro Lys Leu Ser Cys Pro Ser Leu Ser Pro Thr Pro Thr Trp Phe His 86 768 GCA TTC TTC AGC CAT GAC ATC CTC ACT CCA GGA GCT CAG CAG CCA GGG 815 87 Ala Phe Phe Ser His Asp Ile Leu Thr Pro Gly Ala Gln Gln Pro Gly 102 816 CCA TGC CCT GCC CTG CCT TGC ACT TGC TCT GCC CTG GTT CTA CAC TGG 863 103 Pro Cys Pro Ala Leu Pro Cys Thr Cys Ser Ala Leu Val Leu His Trp 118 864 CCC TGG ACC CGC AGG CCA GCA CAG TTC TGT GGC CTC TGC ACC AGG GTT 911 119 Pro Trp Thr Arg Arg Pro Ala Gln Phe Cys Gly Leu Cys Thr Arg Val 134 912 TCA CTC AAG GAG GAG TGG GGG CAG AGA GTG TGG GTG AGC CAG CGT TCC 959 135 Ser Leu Lys Glu Glu Trp Gly Gln Arg Val Trp Val Ser Gln Arg Ser 150 960 CTG AGG AGG TCT AGA GCT GAC TTT GAG CTT ACG GGT TGT GTT GGG ATA 1007 151 Leu Arg Arg Ser Arg Ala Asp Phe Glu Leu Thr Gly Cys Val Gly Ile 1661008 ATA TTA AAG TGG CTG GTG GGT GCG TAC CGT GTT GCA TGC TCT GTG CTG 1055 167 Ile Leu Lys Trp Leu Val Gly Ala Tyr Arg Val Ala Cys Ser Val Leu 1821056 GGG GTT CGT GTA TAT GTC TTA TTT CAT GCA GTA ATC CTA GGA GAC AGA 1103 183 Gly Val Arg Val Tyr Val Leu Phe His Ala Val Ile Leu Gly Asp Arg 1981104 TTC TGT TAT GTA GGA GAA CAC TGA GGC TTA GAA GAG TTT ACA TGA CTT 1151 199 Phe Cys Tyr Val Gly Glu His *** 2061152 GTC AGC TAA TAG TAG CCA ACC TGG ATT CCA AGA CAG GTC TGT CTG ACT 11991200 CCA AAG ACC TTG CCC TTT GCT CTA TGT CCA AAG GTG AGT CTA AAT GTC 12471248 CAG CCA CAC CTG TAT GCG GTG ATG CCT GTG GGT TTG GGT GTG GGA GCC 12951296 TGC AGG TAC AAT GCC TGT GAA AGG TAT AAT ATG TGT GTA CGG GCA CAG 13431344 TAG CTT ATG CCT GTA ATC CCA GCA CTT TGG GAG GCC AAG GCA GGA GGA 13911392 TCA CCT GTG GTC AGG AGT TCA AGA ACA GCC TGA TCA ACA AGG TGA AAC 14391440 CTC GTC TCT ACT AAA AAA AAA AAT ACA AAA ATT AGC TGG GCG AGG CTG 14871488 AGA CAG GAG AAT TGC TTG AAC CCA GGA GGC AGA GGT TGC AGT GAG CTG 15351536 AGA TTG CAC CAC TGC ACT CCA GCC TGG GTG ACA GAG TGA GAC TCC ATT 15831584 TCA AAA AAA AAA GAA AGA AAG GTA TAA CAC AAG CCT AAG TGT AAA GGC 16311632 ATT CGT GTG GCA GAT GCA CAT CTA CGT GAA CTT TGG TGA GTA TGA ACC 16791680 CAC TGC TTC TTC CTT GGA GTG TAC CTC CCA TCC CAT GTC CTT GTT AAG 17271728 GCC ACT CTG CAT GTC ACC TGG GAA GCA TCT TCT GTT GCC GTC CCA TCA 17751776 GTT GCT GAG CCA AAA CCA CCT GCC GAG GAT GGC GAT TCA AGT AAG AGT 18231824 ACG TTT CTC ATG GGT TGG AAG AGA TTT GGG GTC ACT TAC TGG CTG GTG 18711872 ACC TTG AGT GAG TTA TCG CCC TTC ATA GGC TCA AGT GTT CTG ATG TCT 19191920 AAA GTC AGG GAG GTG GGC TGG AAC CTA AAC CTA GCC ACT TAG GTT ATC 19671968 TCT CTC TGA GAG TTT CTA ATG CTC TGC AAG AGC ATG GTG TGG AGT GTG 20152016 GCT TAC TGG GCA TGT TGT GGG CAG GCC AGG ATT AAA TTA ATT AAT GGG 20632064 AAA GCA CTT TGC CAA TTG GAA AGC ACC ACA AAA ATT TCA ACA TTT ACA 21112112 TAA GGT GTC ATT ATC ACG ACT ATT ATT TGC TTA ATG GGT CCA GAG CTT 21592160 GCA GCT GGT TTG TGT ATG TTG GAG CTT GTG CAT GTG TGT TTT TTA AAA 22072208 ACC GTG TGT GAC TGT GTG TGT ATT TTG TTG TGG ATG TGT CCG TCT GAG 22552256 TAT CTA TTT TGA TAT ATG TAT TTA CAG TAG GGG TTC TAG AGA GTG CAA 23032304 GTG GGT GCT GCA CTG GGA ATG GGG AAG GCC TGA GTT ATA CGT CCA GTT 23512352 TTC CAG TGA CTA GCA ATT AAA AAA AAA AAA AAA AAA AAA AAA AAA AAA 23992400 AAA AAA AAA AAA AAA AAA AAA AAA AAA AAA AAA AAA AAA AAA AAA AAA 24472448 AAA AAA AAA AAA AAA A 2463

7.PP7664

A： ( SEQ ID NO：19 ) ：2078bp 1 GGCAGGCCAG GACTAGTTCC ACGGCCCTGA GCATGCGTTA GCCCCTTCTT GCCTCCATGC 61 ATCAGTTTAC CTCGGAGTGA GCTGCGGGAG ACGTCTCCCT GCCTGGCCGG GGCGGCTCTG121 TCGTAGCGGA GGGCAGCGGT GGTGCAGATC CGGAGCCGGA GCCGGAGCCG CGCCGCGCCG181 CACCATGGCG CCCACCCTGG CCACTGCCCA TCGGCGCCGC TGGTGGATGG CCTGCACGCC241 CGTGCTGGAG AACCTCCTCT TCTCGGCAGT CCTCCTGGGC TGGGGCTCGC TGCTCATCAT301 GCTCAAGTCA GAGGGCTTTT ACTCCTACCT GTGTACCGAG CCAGAGAATG TCACCAATGG361 CACAGTGGGC GGCACAGCAG AGCCGGGGCA CGAGGAGGTG AGCTGGATGA ACGGCTGGCT421 CAGCTGCCAG GCCCAGGACG AGATGCTAAA TTTGGCCTTC ACTGTGGGCT CCTTTCTGCT481 CAGTGCCATC ACCCTGCCCC TGGGTATCGT CATGGACAAG TATGGCCCGA GGAAGCTCAG541 GCTGCTGGGC AGCGCCTGCT TCGCGGTTTC CTGCTTGCTG ATTGCGTACG GAGCAAGTAA601 ACCAAACGCT CTCTCCGTGC TCATCTTCAT CGCCCTGGCT CTGAATGGCT TTGGTGGGAT661 GTGTATGACC TTCACCTCAT TAACACTGCC CAACATGTTC GGCGACCTTC GGTCCACGTT721 TATTGCCTTG ATGATTGGGT CCTACGCCTC CTCGGCAGTC ACCTTTCCAG GAATCAAGCT781 CATCTATGAT GCTGGTGTCT CCTTCATCGT CGTCCTCGTG GTCTGGGCCG GCTGCTCCGG 841 GCTGGTTTTC CTCAACTGCT TCTTTAACTG GCCCCTTGAG CCCTTCCCGG GGCCGGAGGA 901 CATGGACTAC TCGGTGAAGA TCAAGTTCAG CTGGCTGGGC TTTGACCACA AGATCACAGG 961 GAAGCAGRTTC TACAAGCAGG TGACCACGGT GGGCCGGCGC CTGAGTGTGG GCAGCTCCAT1021 GAGGAGTGCC AAGGAGCAGG TGGCGCTGCA GGAGGGCCAC AAGCTGTGCC TGTCCACCGT1081 CGACCTGGAG GTGAAGTGCC AGCCGGATGC CGCAGTGGCC CCCTCCTTCA TGCACAGCGT1141 GTTCAGCCCC ATCCTGCTGC TCAGCCTGGT CACCATGTGC GTCACGCAGC TGCGGCTCAT1201 CTTCTACATG GGGGCTATGA ACAACATCCT CAAGTTCCTC GTCAGCGGCG ACCAGAAGAC1261 AGTTGGCCTC TACACCTCCA TCTTCGGCGT GCTCCAGCTG CTGTGCCTGC TGACGGCCCC1321 CGTCATTGGC TACATCATGG ACTGGAGGCT GAAGGAGTGT GAAGACGCCT CCGAGGAGCC1381 CGAGGAGAAA GACGCCAACC AGTGCGTAGG CAGGGCCGGT GCCCCGGCTC CCAGCCCGCA1441 GCCCCTGCAG AAAGACCCCA GAGCTGCATG TCAGGCACAG GGTGGGTGGG ACAGAGGGAG1501 AGAGCAATGC ACTCCAGCTC CTCCCGGAGC CCTTAGAGAG GCTCACTCAT TCAGCTCAGC1561 ATGCGTTTCA ACTGCTCCCC TCTTTATGGA AATTGTTTGG AATGCAATGG AAATGCTAGA1621 GTTTGAGGCC AGGTGCGGTG ACTCATGCCT GTAATCCCAA GCACTTTGAA AGGTTGGGGT1681 AGGAAGATCA CTTGAGGCCA GGAGTTGGAG ACCAGCCTGG GAAACATGGC CAGCCCCCAC1741 TCCCCGTCTC TACAAAAAAT TTAAAAATTG GCCAGGGAGG GTGGTTCATG CCTATAATAC1801 CAACACTTTG GAAGGTTGAG GTGAGTGAAT TGCTTGAGCC CAGGAGTTAG TGACCAGCCT1861 GGCCAATGTG GTAAAACCCG GTCTTTACTA AAAATACAAA AAATTAGCCA GGTGCGGTGT1921 CGGCGCGCGC CTGTAATCCC AGCTACTCAG GAGGCTGAGG CGCGAGAATT GCTTGAACCC1981 GGGAGGTGGA GGTTGCAGTG AGCCGAGATC ACGCCATTGC ACTTCCAGCC TGGGCACCAG2041 AGCAAGACTG TCTCAAAAAG AAAAAAAAAA AAAAAAAA

B： ( SEQ ID NO：20 ) ：489 1 MAPTLATAHR RRWWMACTPV LENLLFSAVL LGWGSLLIML KSEGFYSYLC TEPENVTNGT 61 VGGTAEPGHE EVSWMNGWLS CQAQDEMLNL AFTVGSFLLS AITLPLGIVM DKYGPRKLRL121 LGSACFAVSC LLIAYGASKP NALSVLIFIA LALNGFGGMC MTFTSLTLPN MFGDLRSTFT181 ALMIGSYASS AVTFPGIKLI YDAGVSFIVV LVVWAGCSGL VFLNCFFNWP LEPFPGPEDM241 DYSVKIKFSW LGFDHKITGK QFYKQVTTVG RRLSVGSSMR SAKEQVALQE GHKLCLSTVD301 LEVKCQPDAA VAPSFMHSVF SPILLLSLVT MCVTQLRLIF YMGAMNNILK FLVSGDQKTV361 GLYTSIFGVL QLLCLLTAPV IGYIMDWRLK ECEDASEEPE EKDANQCVGR AGAPAPSPQP421 LQKDPRAACQ AQGGWDRGRE QCTPAPPGAL REAHSFSSAC VSTAPLFMEI VWNAMEMLEF481 EARCGDSCL

C. Nucleotide and amino acid composite sequence (SEQ ID NO:21)

Clone number: PP7664

Start code: 185 ATG stop coding: 1652 TAA

：53338.39 1 G GCA GGC CAG GAC TAG TTC CAC GGC CCT GAG CAT GCG TTA GCC CCT 46 47 TCT TGC CTC CAT GCA TCA GTT TAC CTC GGA GTG AGC TGC GGG AGA CGT 94 95 GTC CCT GCC TGG CCG GGG CGG CTC TGT CGT AGC GGA GGG CAG CGG TGG 142143 TGC AGA TCC GGA GCC GGA GCC GGA GCC GCG CCG CGC CGC ACC ATG GCG 190 1 Met Ala 2191 CCC ACC CTG GCC ACT GCC CAT CGG CGC CGC TGG TGG ATG GCC TGC ACG 238 3 Pro Thr Leu Ala Thr Ala His Arg Arg Arg Trp Trp Met Ala Cys Thr 18239 CCC GTG CTG GAG AAC CTC CTC TTC TCG CCA GTC CTC CTG GGC TGG GGC 286 19 Pro Val Leu Glu Asn Leu Leu Phe Ser Ala Val Leu Leu Gly Trp Gly 34287 TCG CTG CTC ATC ATG CTC AAG TCA GAG GGC TTT TAC TCC TAC CTG TGT 334 35 Ser Leu Leu Ile Met Leu Lys Ser Glu Gly Phe Tyr Ser Tyr Leu Cys 50 335 ACC GAG CCA GAG AAT GTC ACC AAT GGC ACA GTG GGC GGC ACA GCA GAG 382 51 Thr Glu Pro Glu Asn Val Thr Asn Gly Thr Val Gly Gly Thr Ala Glu 66 383 CCG GGG CAC GAG GAG GTG AGC TGG ATG AAC GGC TGG CTC AGC TGC CAG 430 67 Pro Gly His Glu Glu Val Ser Trp Met Asn Gly Trp Leu Ser Cys Gln 82 431 GCC CAG GAC GAG ATG CTA AAT TTG GCC TTC ACT GTG GGC TCC TTT CTG 478 83 Ala Gln Asp Glu Met Leu Asn Leu Ala Phe Thr Val Gly Ser Phe Leu 98 479 CTC AGT GCC ATC ACC CTG CCC CTG GGT ATC GTC ATG GAC AAG TAT GGC 526 99 Leu Ser Ala Ile Thr Leu Pro Leu Gly Ile Val Met Asp Lys Tyr Gly 114 527 CCG AGG AAG CTC AGG CTG CTG GGC AGC GCC TGC TTC GCG GTT TCC TGC 574 115 Pro Arg Lys Leu Arg Leu Leu Gly Ser Ala Cys Phe Ala Val Ser Cys 130 575 TTG CTG ATT GCG TAC GGA GCA AGT AAA CCA AAC GCT CTC TCC GTG CTC 622 131 Leu Leu Ile Ala Tyr Gly Ala Ser Lys Pro Asn Ala Leu Ser Val Leu 146 623 ATC TTC ATC GCC CTG GCT CTG AAT GGC TTT GGT GGG ATG TGT ATG ACC 670 147 Ile Phe Ile Ala Leu Ala Leu Asn Gly Phe Gly Gly Met Cys Met Thr 162 671 TTC ACC TCA TTA ACA CTG CCC AAC ATG TTC GGC GAC CTT CGG TCC ACG 718 163 Phe Thr Ser Leu Thr Leu Pro Asn Met Phe Gly Asp Leu Arg Ser Thr 178 719 TTT ATT GCC TTG ATG ATT GGG TCC TAC GCC TCC TCG GCA GTC ACC TTT 766 179 Phe Ile Ala Leu Met Ile Gly Ser Tyr Ala Ser Ser Ala Val Thr Phe 194 767 CCA GGA ATC AAG CTC ATC TAT GAT GCT GGT GTC TCC TTC ATC GTC GTC 814 195 Pro Gly Ile Lys Leu Ile Tyr Asp Ala Gly Val Ser Phe Ile Val Val 210 815 CTC GTG GTC TGG GCC GGC TGC TCC GGG CTG GTT TTC CTC AAC TGC TTC 862 211 Leu Val Val Trp Ala Gly Cys Ser Gly Leu Val Phe Leu Asn Cys Phe 226 863 TTT AAC TGG CCC CTT GAG CCC TTC CCG GGG CCG GAG GAC ATG GAC TAC 910 227 Phe Asn Trp Pro Leu Glu Pro Phe Pro Gly Pro Glu Asp Met Asp Tyr 242 911 TCG GTG AAG ATC AAG TTC AGC TGG CTG GGC TTT GAC CAC AAG ATC ACA 958 243 Ser Val Lys Ile Lys Phe Ser Trp Leu Gly Phe Asp His Lys Ile Thr 258 959 GGG AAG CAG TTC TAC AAG CAG GTG ACC ACG GTG GGC CGG CCC CTG AGT 1006 259 Gly Lys Gln Phe Tyr Lys Gln Val Thr Thr Val Gly Arg Arg Leu Ser 2741007 GTG GGC AGC TCC ATG AGG AGT GCC AAG GAG CAG GTG GCG CTG CAG GAG 1054 275 Val Gly Ser Ser Met Arg Ser Ala Lys Glu Gln Val Ala Leu Gln Glu 2901055 GGC CAC AAG CTG TGC CTG TCC ACC GTC GAC CTG GAG GTG AAG TGC CAG 1102 291 Gly His Lys Leu Cys Leu Ser Thr Val Asp Leu Glu Val Lys Cys Gln 3061103 CCG GAT GCC GCA GTG GCC CCC TCC TTC ATG CAC AGC GTG TTC AGC CCC 1150 307 Pro Asp Ala Ala Val Ala Pro Ser Phe Met His Ser Val Phe Ser Pro 3221151 ATC CTG CTG CTC AGC CTG GTC ACC ATG TGC GTC ACG CAG CTG CGG CTC 1198 323 Ile Leu Leu Leu Ser Leu Val Thr Met Cys Val Thr Gln Leu Arg Leu 3381199 ATC TTC TAC ATG GGG GCT ATG AAC AAC ATC CTC AAG TTC CTG GTC AGC 1246 339 Ile Phe Tyr Met Gly Ala Met Asn Asn Ile Leu Lys Phe Leu Val Ser 3541247 GGC GAC CAG AAG ACA GTT GGC CTC TAC ACC TCC ATC TTC GGC GTG CTC 1294 355 Gly Asp Gln Lys Thr Val Gly Leu Tyr Thr Ser Ile Phe Gly Val Leu 3701295 CAG CTG CTG TGC CTG CTG ACG GCC CCC GTC ATT GGC TAC ATC ATG GAC 1342 371 Gln Leu Leu Cys Leu Leu Thr Ala Pro Val Ile Gly Tyr Ile Met Asp 3861343 TGG AGG CTG AAG GAG TGT GAA GAC GCC TCC GAG GAG CCC GAG GAG AAA 1390 387 Trp Arg Leu Lys Glu Cys Glu Asp Ala Ser Glu Glu Pro Glu Glu Lys 4021391 GAC GCC AAC CAG TGC GTA GGC AGG GCC GGT GCC CCG GCT CCC AGC CCG 1438 403 Asp Ala Asn Gln Cys Val Gly Arg Ala Gly Ala Pro Ala Pro Ser Pro 4181439 CAG CCC CTG CAG AAA GAC CCC AGA GCT GCA TGT CAG GCA CAG GGT GGG 1486 419 Gln Pro Leu Gln Lys Asp Pro Arg Ala Ala Cys Gln Ala Gln Gly Gly 4341487 TGG GAC AGA GGG AGA GAG CAA TGC ACT CCA GCT CCT CCC GGA GCC CTT 1534 435 Trp Asp Arg Gly Arg Glu Gln Cys Thr Pro Ala Pro Pro Gly Ala Leu 4501535 AGA GAG GCT CAC TCA TTC AGC TCA GCA TGC GTT TCA ACT GCT CCC CTC 1582 451 Arg Glu Ala His Ser Phe Ser Ser Ala Cys Val Ser Thr Ala Pro Leu 4661583 TTT ATG GAA ATT GTT TGG AAT GCA ATG GAA ATG CTA GAG TTT GAG GCC 1630 467 Phe Met Glu Ile Val Trp Asn Ala Met Glu Met Leu Glu Phe Glu Ala 4821631 AGG TGC GGT GAC TCA TGC CTG TAA TCC CAA GCA CTT TGA AAG GTT GGG 1678 483 Arg Cys Gly Asp Ser Cys Leu *** 4901679 GTA GGA AGA TCA CTT GAG GCC AGG AGT TGG AGA CCA GCC TGG GAA ACA 17261727 TGG CCA GCC CCC ACT CCC CGT CTC TAC AAA AAA TTT AAA AAT TGG CCA 17741775 GGG AGG GTG GTT CAT GCC TAT AAT ACC AAC ACT TTG GAA GGT TGA GGT 18221823 GAG TGA ATT GCT TGA GCC CAG GAG TTA GTG ACC AGC CTG GCC AAT GTG 18701871 GTA AAA CCC GGT CTT TAC TAA AAA TAC AAA AAA TTA GCC AGG TGC GGT 19181919 GTC GGC GCG CGC CTG TAA TCC CAG CTA CTC AGG AGG CTG AGG CGC GAG 19661967 AAT TGC TTG AAC CCG GGA GGT GGA GGT TGC AGT GAG CCG AGA TCA CGC 20142015 CAT TGC ACT TCC AGC CTG GGC ACC AGA GCA AGA CTG TCT CAA AAA GAA 20622063 AAA AAA AAA AAA AAA A 2078

8.PP7827

A： ( SEQ ID NO：22 ) ：2498bp 1 GTTTTATTGC CACAACTAAC CTCCTCGGAC TCCTGCCTCA CTCATTTACA CCAACCACCC 61 AACTATCTAT AAACCTAGCC ATGGCCATCC CCTTATGAGC GGGCGCAGTG ATTATAGGCT121 TTCGCTCTAA GATTAAAAAT GCCCTAGCCC ACTTCTTACC ACAAGGCACA CCTACACCCC181 TTATCCCCAT ACTAGTTATT ATCGAAACCA TCAGCCTACT CATTCAACCA ATAGCCCTGG241 CCGTACGCCT AACCGTAACA TTACTGCAGG CCACCTACTC ATGCACCTAA TTGGAAGCGC 301 CACCCTAGCA ATATCAACCA TTAACCTTCC CTCTACACTT ATCATCTTGA CAATTCTAAT 361 TCTACTGACT ATCCTAGAAA TCGCTGTCGC TTAATCCAAG CCTACGTTTT CACACTTCTA 421 GTAAGCCTCT ACCTGCACGA CAACACATAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA 481 AAAAAAAAAA AAAAAAAAAA AAAAAAACCT TCCCCGCGCC GGCCGGGTCC CGCCCGTTCC 541 CCGGCACCAG AAGTTCCTTT GCGCGTCCGA CGGCGACATG GGCGTCCCCA CGGCCCTGGA 601 GGCCGGCAGC TGGCGCTGGG GATCCCTGCT CTTCGCTCTT TTCCTGGCTG CGTCCCTAGG 661 TCCGGTGGCA GCCTTAAAGG TCGCCACGCC GTATTCCCTG TATGTCTGTC CCGAGGGGCA 721 AAACGTCACC CTCACCTGCA GGCTTTTGGG CCCTGTGGAC AAAGGGCACG ATGTGACCTT 781 CTACAAGACG TGGTACCGCA GCTCGAGGGG CGAGGTGCAA ACCTGTTAAA AGCGCCGGCC 841 CATCCGAAAC CTAACGTTCC AGGACCTTCA CCTGCACCAT GGAGGCCACC AGGCTGCCAA 901 CACCAGGCAC GACCTGGCTC AGCGCCACGG GCTGGAGTCG GCCTCCGACC ACCATGGCAA 961 CTTCTCCATC ACCATGCGCA ACCTGACCCT GCTGGATAGC GGCCTCTACT GCTGCCTGGT1021 GGTGGAGATC AGGCACCACC ACTCGGAGGA CAGGGTCCAT GGTGCCATGG AGCTGCAGGT1081 GCAGACAGGC AAAGATGCAC CATCCAACTG TGTGGTGTAC CCATCCTCCT CCCAGGAGAG1141 TGAAAACATC ACGGCTGCAG CCCTGGCTAC GGGTGCCTGC ATCGTAGGAA TCCTCTGCCT1201 CCCCCTCATC CTGCTCCTGG TCTACAAGCA AAGGCAGGCA GCCTCCAACC GCCGTGCCCA1261 GGAGCTGGTG CGGATGGACA GCAACATTCA AGGGATTGAA AACCCCGGCT TTGAAGCCTC1321 ACCACCTGCC CAGGGGATAC CCGAGGCCAA AGTCAGGCAC CCCCTGTCCT ATGTGGCCCA1381 GCGGCAGCCT TCTGAGTCTG GGCGGCATCT GCTTTCGGAG CCCAGCACCC CCCTGTCTCC1441 TCCAGGCCCC GGAGACGTCT TCTTCCCATC CCTGGACCCT GTCCCTGACT CTCCAAACTT1501 TGAGGTCATC TAGCCCAGCT GGGGGACAGT GGGCTGTTGT GGCTGGGTCT GGGGCAGGTG1561 CATTTGAGCC AGGGCTGGGT CTGTGAGTGG CCTCCTTGGC CTCGGCCCTG GTTCCCTCCC1621 TCCTGCTCTG GGCTCAGATA CTGTGACATC CCAAAAGCCC AGCCCCTCAA CCCCTCTGGA1681 TGCTACATGG GGATGCTGGA CGGCTCAGCC CCTGTTCCAA GGATTTTGGG GTGCTGAGAT1741 TCTCCCCTAG AGACCTGAAA TTCACCAGCT ACAGATGCCA AATGACTTAC ATCTTAAGAA1801 GTCTCAAAAC GTCCAGCCCT TCAGCAGCTC TCGTTCTGAG ACATGAGCCT TGGGATGTGG1861 CAGCATCAGT GGGACAAGAT GGACACTGGG CCACCCTCCC AGGCACCAGA CACAGGGCAC1921 GGTGGAGAGA CTTCTCCCCC GTGGCCGCCT TGGCTCCCCC GTTTTGCCCG AGGCTGCTCT1981 TCTGTCAGAC TTCCTCTTTG TACCACAGTG GCTCTGGGGC CAGGCCTGCC TGCCCACTGG2041 CCATCGCCAC CTTCCCCAGC TGCCTCCTAC CAGCAGTTTC TCTGAAGATC TGTCAACAGG2101 TTAAGTCAAT CTGGGGCTTC CACTGCCTGC ATTCCAGTCC CCAGAGCTTG GTGGTCCCGA2161 AACGGGAAGT ACATATTGGG GCATGGTGGC CTCCGTGAGC AAATGGTGTC TTGGGCAATC2221 TGAGGCCAGG ACAGATGTTG CCCCACCCAC TGGAGATGGT GCTGAGGGAG GTGGGTGGGG2281 CCTTCTGGGA AGGTGAGTGG AGAGGGGCAC CTGCCCCCCG CCCTCCCCAT CCCCTACTCC2341 CACTGCTCAG CGCGGGCCAT TGCAAGGGTG CCACACAATG TCTTGTCCAC CCTGGGACAC2401 TTCTGAGTAT GAAGCGGGAT GCTATTAAAA ACTACATGGG GAAACAGGTG CAAAAAAAAA2461 AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAA

B: aminoacid sequence (SEQ ID NO:23) length: 179 amino acid/11 MRNLTLLDSG LYCCLVVEIR HHHSEHRVHG AMELQVQTGK DAPSNCVVYP SSSQESENIT 61 AAALATGACI VGILCLPLIL LLVYKQRQAA SNRRAQELVR MDSNIQGIEN PGFEASPPAQ121 GIPEAKVRHP LSYVAQRQPS ESGRHLLSEP STPLSPPGPG DVFFPSLDPV PDSPNFEVI

C. Nucleotide and amino acid composite sequence (SEQ ID NO:24)

Clone number: PP7827

Start code: 974 ATG stop coding: 1511 TAG

：19394.03 1 G TTT TAT TGC CAC AAC TAA CCT CCT CGG ACT CCT GCC TCA CTC ATT 4647 TAC ACC AAC CAC CCA ACT ATC TAT AAA CCT AGC CAT GGC CAT CCC CTT 9495 ATG AGC GGG CGC AGT GAT TAT AGG CTT TCG CTC TAA GAT TAA AAA TGC 142 143 CCT AGC CCA CTT CTT ACC ACA AGG CAC ACC TAC ACC CCT TAT CCC CAT 190 191 ACT AGT TAT TAT CGA AAC CAT CAG CCT ACT CAT TCA ACC AAT AGC CCT 238 239 GGC CGT ACG CCT AAC CGT AAC ATT ACT GCA GGC CAC CTA CTC ATG CAC 286 287 CTA ATT GGA AGC GCC ACC CTA GCA ATA TCA ACC ATT AAC CTT CCC TCT 334 335 ACA CTT ATC ATC TTG ACA ATT CTA ATT CTA CTG ACT ATC CTA GAA ATC 382 383 GCT GTC GCT TAA TCC AAG CCT ACG TTT TCA CAC TTC TAG TAA GCC TCT 430 431 ACC TGC ACG ACA ACA CAT AAA AAA AAA AAA AAA AAA AAA AAA AAA AAA 478 479 AAA AAA AAA AAA AAA AAA AAA AAA AAA AAC CTT CCC CGC GCC GGC CGG 526 527 GTC CCG CCC GTT CCC CGG CAC CAG AAG TTC CTT TGC GCG TCC GAC GGC 574 575 GAC ATG GGC GTC CCC ACG GCC CTG GAG GCC GGC AGC TGG CGC TGG GGA 622 623 TCC CTG CTC TTC GCT CTT TTC CTG GCT GCG TCC CTA GGT CCG GTG GCA 670 671 GCC TTA AAG GTC GCC ACG CCG TAT TCC CTG TAT GTC TGT CCC GAG GGG 718 719 CAA AAC GTC ACC CTC ACC TGC AGG CTT TTG GGC CCT GTG GAC AAA GGG 766 767 CAC GAT GTG ACC TTC TAC AAG ACG TGG TAC CGC AGC TCG AGG GGC GAG 814 815 GTG CAA ACC TGT TAA AAG CGC CGG CCC ATC CGA AAC CTA ACG TTC CAG 862 863 GAC CTT CAC CTG CAC CAT GGA GGC CAC CAG GCT GCC AAC ACC AGC CAC 910 911 GAC CTG GCT CAG CGC CAC GGG CTG GAG TCG GCC TCC GAC CAC CAT GGC 958 959 AAC TTC TCC ATC ACC ATG CGC AAC CTG ACC CTG CTG GAT AGC GGC CTC 1006 1 Met Arg Asn Leu Thr Leu Leu Asp Ser Gly Leu 111007 TAC TGC TGC CTG GTG GTG GAG ATC AGG CAC CAC CAC TCG GAG CAC AGG 1054 12 Tyr Cys Cys Leu Val Val Glu Ile Arg His His His Ser Glu His Arg 271055 GTC CAT GGT GCC ATG GAG CTG CAG GTG CAG ACA GGC AAA GAT GCA CCA 1102 28 Val His Gly Ala Met Glu Leu Gln Val Gln Thr Gly Lys Asp Ala Pro 431103 TCC AAC TGT GTG GTG TAC CCA TCC TCC TCC CAG GAG AGT GAA AAC ATC 1150 44 Ser Asn Cys Val Val Tyr Pro Ser Ser Ser Gln Glu Ser Glu Asn Ile 591151 ACG GCT GCA GCC CTG GCT ACG GGT GCC TGC ATC GTA GGA ATC CTC TGC 1198 60 Thr Ala Ala Ala Leu Ala Thr Gly Ala Cys Ile Val Gly Ile Leu Cys 751199 CTC CCC CTC ATC CTG CTC CTG GTC TAC AAG CAA AGG CAG GCA GCC TCC 1246 76 Leu Pro Leu Ile Leu Leu Leu Val Tyr Lys Gln Arg Gln Ala Ala Ser 911247 AAC CGC CGT GCC CAG GAG CTG GTG CGG ATG GAC AGC AAC ATT CAA GGG 1294 92 Asn Arg Arg Ala Gln Glu Leu Val Arg Met Asp Ser Asn Ile Gln Gly 1071295 ATT GAA AAC CCC GGC TTT GAA GCC TCA CCA CCT GCC CAG GGG ATA CCC 1342 108 Ile Glu Asn Pro Gly Phe Glu Ala Ser Pro Pro Ala Gln Gly Ile Pro 1231343 GAG GCC AAA GTC AGG CAC CCC CTG TCC TAT GTG GCC CAG CGG CAG CCT 1390 124 Glu Ala Lys Val Arg His Pro Leu Ser Tyr Val Ala Gln Arg Gln Pro 1391391 TCT GAG TCT GGG CGG CAT CTG CTT TCG GAG CCC AGC ACC CCC CTG TCT 1438 140 Ser Glu Ser Gly Arg His Leu Leu Ser Glu Pro Ser Thr Pro Leu Ser 1551439 CCT CCA GGC CCC GGA GAC GTC TTC TTC CCA TCC CTG GAC CCT GTC CCT 1486 156 PTo Pro Gly Pro Gly Asp Val Phe Phe Pro Ser Leu Asp Pro Val Pro 1711487 GAC TCT CCA AAC TTT GAG GTC ATC TAG CCC AGC TGG GGG ACA GTG GGC 1534 172 Asp Ser Pro Asn Phe Glu Val Ile *** 1801535 TGT TGT GGC TGG GTC TGG GGC AGG TGC ATT TGA GCC AGG GCT GGC TCT 15821583 GTG AGT GGC CTC CTT GGC CTC GGC CCT GGT TCC CTC CCT CCT GCT CTG 16301631 GGC TCA GAT ACT GTG ACA TCC CAA AAG CCC AGC CCC TCA ACC CCT CTG 16781679 GAT GCT ACA TGG GGA TGC TGG ACG GCT CAG CCC CTG TTC CAA GGA TTT 17261727 TGG GGT GCT GAG ATT CTC CCC TAG AGA CCT GAA ATT CAC CAG CTA CAG 17741775 ATG CCA AAT GAC TTA CAT CTT AAG AAG TCT CAA AAC GTC CAG CCC TTC 18221823 AGC AGC TCT CGT TCT GAG ACA TGA GCC TTG GGA TGT GGC AGC ATC AGT 18701871 GGG ACA AGA TGG ACA CTG GGC CAC CCT CCC AGG CAC CAG ACA CAG GGC 19181919 ACG GTG GAG AGA CTT CTC CCC CGT GGC CGC CTT GGC TCC CCC GTT TTG 19661967 CCC GAG GCT GCT CTT CTG TCA GAC TTC CTC TTT GTA CCA CAG TGG CTC 20142015 TGG GGC CAG GCC TGC CTG CCC ACT GGC CAT CGC CAC CTT CCC CAG CTG 20622063 CCT CCT ACC AGC AGT TTC TCT GAA GAT CTG TCA ACA GGT TAA GTC AAT 21102111 CTG GGG CTT CCA CTG CCT GCA TTC CAG TCC CCA GAG CTT GGT GGT CCC 21582159 GAA ACG GGA AGT ACA TAT TGG GGC ATG GTG GCC TCC GTG AGC AAA TGG 22062207 TGT CTT GGG CAA TCT GAG GCC AGG ACA GAT GTT GCC CCA CCC ACT GGA 22542255 GAT GCT GCT GAG GGA CGT GGG TGG GGC CTT CTG GGA AGG TGA GTG GAG 23022303 AGG GGC ACC TGC CCC CCG CCC TCC CCA TCC CCT ACT CCC ACT GCT CAG 23502351 CGC GGG CCA TTG CAA GGG TGC CAC ACA ATG TCT TGT CCA CCC TGG GAC 23982399 ACT TCT GAG TAT GAA GCG GGA TGC TAT TAA AAA CTA CAT GGG GAA ACA 24462447 GGT GCA AAA AAA AAA AAA AAA AAA AAA AAA AAA AAA AAA AAA AAA AAA 24942495 AAA A 2498

9.PP7882

A： ( SEQ ID NO：25 ) ：2383bp 1 GTCAGTCTCC GCCTGCCCTG ACTGCGCCCT CCCACGCAGA CACGGGACTC AATCCGCGCC 61 TCGGCCGTCG GGCTCCTTGG GACTCTGGTG CGCCGGGGCC GGGGCGGGCT CCGGCTGGGG 121 CTCCGCGGCC CCCTGCGGAA GCTGGTGCTG CAGAGTCTCG TGCCGCTGCT GCTGCGCCTG 181 CATGACCCCA GCAGGCACGC TGCTGAGGTC AGCAGCCCCC GACACCATCC CACCCCTATG 241 CCATCCAACA CTCACCACTC CCACCGTGCC TCCCCTCCGA CAATTACAGG TCAGGGACTC 301 ACCCATCCCA AGGACCTCAG TGGCAGGTGT GACGGGCGGC CAGGTTACTA CTGCTCTTCC 361 CTTGAGCAGA ATCAATCCGG TTTCCTGCCC TGCGCTCTTC TGCCCCTCAC CCGATGCCTT 421 TGCTCCCCCT CTTCCCACCC CAACTTTTGC CTTTTTACTT CCTGGACCCC TGACCCGGCT 481 CACTTCCCCT ATCCCAGAGC TCAGAGTGGA CCCTGGCCCG CTGTGACCAC GCCTTTTGCT 541 GGGGCCTGCT GGAGGAGTTG GTCACCGTGG CCCACTATGA CAGCCCCGAG GCCCTGAGCC 601 ACCTCTGCTG CCGCCTGGTC AGTAGGGGAA GCAAGGTGAC CGCAAGGGGG TATGATCAGC 661 AGCCCACTTG TTCCAGGGTT CACCGGGGCC CCCAACCGTT TCTACTGCAG CCAAACCAGA 721 TAGGCTACTG GTGGGGCAAG TCCAAGGTCT CCGACCATGC CACCTGCCCT GGGGGCTCCC 781 CTGGAACCCC GGCCCCTGGA TTCACCTCTG CAGCCTCCTC CGCACTCAGG ATCAGCCCTC 841 CTGTCCTGCC ACTAGCCCTT TTGTCCCCAG GTTCAGCGAT ACCCAGGCCA CGTGCCCAAC 901 TTCCTGAGCC AGACCCAGGG CTACCTGCGG AGTCCACAGG ACCCCCTGCG CCGGGCAGCC 961 ACCGTGCTTA TAGGCTTCCT TGTCCACCAC GCCAGCCCCG GCTGTGTCAA CCAGGACCTG1021 CTGGACTCCC TGTTCCACGA CCTAGGGCGG CTCCAGAGCG ACCCCAAGCC GGCCGTGGGC1081 GCGGCAGCGC ACGTGTCCGC TCAGCAGGTG GCGATGCTGG CCCGCGCCCG GGGCTGCCCC1141 CGCGGGCCCC GCCTTCTCCG CATCGCCCCG CGCCCCGCCC GGCCCCCACC AGTCTTCGCC1201 GACAGCCCCT TCCAGCGCCG GAGCGTCGCG GGCCGCTGGG GCTGCTCCGG ACCCCGCCGA1261 GCCTGAGGCT CGGGGCTGGG GCCCGAGGGC CAGGGTCCGA CTCGGGCACC CCACGCGCAT1321 AGCAGCCTGT CCCCGCCCTG ACGGAGGGGC TCCCTGGGCC TGGTGCTGGA CGCCAATGCC1381 CTCCCCCACC CCCCACCCCC GTGACCCCTG TTCAGGCACC CGCCACCCTG ATGGTGACAG1441 AGGGGGACAG CCAGCACCCA TCTGTCCCCG TCAGGCCTCT TCCTCTCACA GCCCCCTCGA1501 CCATGCCCCA TGCCCCAACC TTGGGCCTGG CTCCTGGCCC AGATGGCACC TGGCCTCTTG1561 AGTCTGCTGG GGGACCCCAA AGTTGGTGGT CCCATAGCCT GCCCTCCTGG GTCTCCACCT1621 CATGCCTGGA CAGGACGCTG TGGCCTGTCC GGGCCTTGGC CAGCCCTGCA GCTGCACCCC1681 CGATCCTCAT CCCTCACCCC ATTCCCTGCC AGCATCCTAA GGCTCCTGGC GGGCATCCTC1741 TCTGCTCAAA ATTATTGACC TGTCTCCCGG CCACACCTGC TGTGCCCTCT CAGCCAGGCC1801 ATCATCACCC CCTGTTCATT ATGTCAGGCC TCATGGGAGC CTGGCCTTCT CCAGAAGCTG1861 GCCCCGGCGT CCTCCCAAGC TGGACCACGT AGGCCCCAGA TCACACCTGG GGGTCCAGAT1921 GTAGGGGTCC CGTGTGCACG CCCAATCAGA CCGAGCACTT GTGACACTAC CCCAACACCT1981 CTCCCAGGGC TGAATGAGGA ACGCGCCACT GGACACATGA GGAAGAGGCT GCCCTGGGAG2041 CTACTGATGC TGTGACCTCA CCTCTCTGGC TTTGGGCGGC AGGTCCCTGC ACCTAGGATG2101 CCTGCCTGGA AATGTCCTTG CATTCGTGGC CTCCTTCACA GCCTCCTCCT CAGAGAAGCC2161 TCTGCGAGTG CACAGGGAGT GTGTGCAGCC TTGTGAAGGG CTGGGACCAC TTGCCCAGAC2221 TGGGGCCCCT CAGGCACAGG CGTGGGGTCC TACTGACCTG TCTCCCCAGC TCCCACACAG2281 AAAGCATCTA AAATAAACAC ACGTGGATGG AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA2341 AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAA

B: aminoacid sequence (SEQ ID NO:26) length: 153 amino acid/11 MVTEGDSQHP SVPVRALALT APWSMPHAPT LGLAPGPDGT WPLESAGGPQ SWWSHSLPSW 61 VSTSCLDRTL WPVRALASPA AAPPILIPHP IPCQHPKAPG GHPLCSKLLT CLPATPAVPS121 QPGHHHPLFI MSGLMGAWPS PEAGPGVLPS WTT

C. Nucleotide and amino acid composite sequence (SEQ ID NO:27)

Clone number: PP7882

Start code: 1431 ATG stop coding: 1890 TAG

：15965.48 1 GT CAG TCT CCG CCT GCC CTG ACT GCG CCC TCC CAC GCA GAC ACG GGA 47 48 CTC AAT CCG CGC CTC GGC CGT CGG GCT CCT TGG GAC TCT GGT GCG CCG 95 96 GGG CCG GGG CGG GCT CCG GCT GGG GCT CCG CGG CCC CCT GCG GAA GCT 143 144 GGT GCT GCA GAG TCT CGT GCC GCT GCT GCT GCG CCT GCA TGA CCC CAG 191 192 CAG GGA CGC TGC TGA GGT CAG CAG CCC CCG ACA CCA TCC CAC CCC TAT 239 240 GCC ATC CAA CAC TCA CCA CTC CCA CCG TGC CTC CCC TCC GAC AAT TAC 287 288 AGG TCA GGG ACT CAC CCA TCC CAA GGA CCT CAG TGG CAG GTG TGA CGG 335 336 GCG GCC AGG TTA CTA CTG CTC TTC CCT TGA GCA GAA TCA ATC CGG TTT 383 384 CCT GCC CTG GGC TCT TCT GCC CCT CAC CCG ATG CCT TTG CTC CCC CTC 431 432 TTC CCA CCC CAA CTT TTG CCT TTT TAC TTC CTG GAC CCC TGA CCC GGC 479 480 TCA CTT CCC CTA TCC CAG AGC TCA GAG TGG ACC CTG GCC CGC TGT GAC 527 528 CAC GCC TTT TGC TGG CTG CTG CTG GAG GAG TTG GTC ACC GTG GCC CAC 575 576 TAT GAC AGC CCC GAG GCC CTG AGC CAC CTC TGC TGC CGC CTG GTC AGT 623 624 AGG GGA AGC AAG GTG ACC GCA AGG GGG TAT GAT CAG CAG CCC ACT TGT 671 672 TCC AGG GTT CAC CGG GGC CCC CAA CCG TTT CTA CTG CAG CCA AAC CAG 719 720 ATA GGC TAC TGG TGG GGC AAG TCC AAG GTC TCC GAC CAT GCC ACC TGC 767 768 CCT GGG GGC TCC CCT GGA ACC CCG GCC CCT GGA TTC AGC TCT GCA GCC 815 816 TCC TCC GCA CTC AGG ATC AGC CCT CCT GTC CTG CCA CTA GCC CTT TTG 863 864 TCC CCA GGT TCA GCG ATA CCC AGG CCA CGT GCC CAA CTT CCT GAG CCA 911 912 GAC CCA GGG CTA CCT GCG GAG TCC ACA GGA CCC CCT GCG CCG GGC AGC 959 960 CAC CGT GCT TAT AGG CTT CCT TCT CCA CCA CGC CAG CCC CGG CTG TGT 10071008 CAA CCA GGA CCT GCT GGA CTC CCT GTT CCA GGA CCT AGG GCG GCT GCA 10551056 GAG CGA CCC CAA GCC GGC CGT GGC CGC GGC AGC GCA CGT GTC CGC TCA 11031104 GCA GGT GGC GAT GCT GGC CCG CGC CCG GGG CTG CCC CCG CGG GCC CCG 11511152 CCT TCT CCG CAT CGC CCC GCG CCC CGC CCG GCC CCC ACC AGT CTT CGC 11991200 CGA CAG CCC CTT CCA GCG CCG GAG CGT CGC GGG CCG CTG GGG CTG CTC 12471248 CGG ACC CCG CCG AGC CTG AGG CTC GGG GCT GGG GCC CGA GGG CCA GGG 12951296 TCC GAC TCG GGC ACC CCA CGC GCA TAG CAG CCT GTC CCC GCC CTG ACG 13431344 GAG GGG CTC CCT GGG CCT GGT GCT GGA CGC CAA TGC CCT CCC CCA CCC 13911392 CCC ACC CCC GTG ACC CCT GTT CAG GCA CCC GCC ACC CTG ATG GTG ACA 1439 1 Met Val Thr 31440 GAG GGG GAC AGC CAG CAC CCA TCT GTC CCC GTC AGG GCT CTT GCT CTC 1487 4 Glu Gly Asp Ser Gln His Pro Ser Val Pro Val Arg Ala Leu Ala Leu 191488 ACA GCC CCC TGG ACC ATG CCC CAT GCC CCA ACC TTG GGC CTGG GCT CCT 1535 20 Thr Ala Pro Trp Ser Met Pro His Ala Pro Thr Leu Gly Leu Ala Pro 351536 GGC CCA GAT GGC ACC TGG CCT CTT GAG TCT CCT GGG GGA CCC CAA AGT 1583 36 Gly Pro Asp Gly Thr Trp Pro Leu Glu Ser Ala Gly Gly Pro Gln Ser 511584 TGG TGG TCC CAT AGC CTG CCC TCC TGG GTC TCC ACC TCA TGC CTG GAC 1631 52 Trp Trp Ser His Ser Leu Pro Ser Trp Val Ser Thr Ser Cys Leu Asp 671632 AGG ACG CTG TGG CCT GTC CGG GCC TTG GCC AGC CCT GCA GCT GCA CCC 1679 68 Arg Thr Leu Trp Pro Val Arg Ala Leu Ala Ser Pro Ala Ala Ala Pro 831680 CCG ATC CTC ATC CCT CAC CCC ATT CCC TGC CAG CAT CCT AAG GCT CCT 1727 84 Pro Ile Leu Ile Pro His Pro Ile Pro Cys Gln His Pro Lys Ala Pro 991728 GGC GGG CAT CCT CTC TGC TCA AAA TTA TTG ACC TGT CTC CCG GCC ACA 1775 100 Gly Gly His Pro Leu Cys Ser Lys Leu Leu Thr Cys Leu Pro Ala Thr 1151776 CCT GCT GTG CCC TCT CAG CCA GGC CAT CAT CAC CCC CTG TTC ATT ATG 1823 116 Pro Ala Val Pro Ser Gln Pro Gly His His His Pro Leu Phe Ile Met 1311824 TCA GGC CTC ATG GGA GCC TGG CCT TCT CCA GAA GCT GGC CCC GGC GTC 1871 132 Ser Gly Leu Met Gly Ala Trp Pro Ser Pro Glu Ala Gly Pro Gly Val 1471872 CTC CCA AGC TGG ACC ACG TAG GCC CCA GAT CAC ACC TGG GGG TCC AGA 1919 148 Leu Pro Ser Trp Thr Thr *** 1541920 TGT AGG GGT CCC GTG TGC ACG CCC AAT CAG ACC GAG CAC TTG TGA CAC 19671968 TAC CCC AAC ACC TCT CCC AGG GCT GAA TGA GGA ACG CGC CAC TGG ACA 20152016 CAT GAG GAA GAG GCT GCC CTG GGA GCT ACT GAT GCT GTG ACC TCA CCT 20632064 CTC TGG CTT TGG GCG GCA GGT CCC TGC ACC TAG GAT GCC TGC CTG GAA 21112112 ATG TCC TTG CAT TCG TGG CCT CCT TCA CAG CCT CCT CCT CAG AGA AGC 21592160 CTC TGC GAG TGC ACA GGG AGT GTG TGC AGC CTT GTG AAG GGC TGG GAC 22072208 CAC TTG CCC AGA CTG GGG CCC CTC AGG CAC AGG CGT GGG GTC CTA CTG 22552256 ACC TGT CTC CCC AGC TCC CAC ACA GAA AGC ATC TAA AAT AAA CAC ACG 23032304 TGG ATG GAA AAA AAA AAA AAA AAA AAA AAA AAA AAA AAA AAA AAA AAA 23512352 AAA AAA AAA AAA AAA AAA AAA AAA AAA AAA AA 2383

10.PP8038

A： ( SEQ ID NO：28 ) ：1828bp 1 GAGACAAGAA CCTGGCTGAA GAAAACTTGG TCCAAACTGC ATCAGAGGTG GGGGTGGTCG61 CTGTTCCCAA GGGAAAGGTC CTGCTTAAAC AGGTGCTTTG TGAGTGGAAA CGTGGCCAGA 121 GTGCGGCGGG TGCTTTGTGA GTGGAAATGT GGCCAGAGTG CGGCGGATGC TTTGTGAGTG 181 GAAACGTGGC CTTCTCTGGA AGCCCTGGGG AGGGGCTTTC CGACTGAGAG GAAGGCCTCG 241 CATCTGCCCA CCGCCCAGTC CTGGGCCTCA CAGTGAGGAT GCAGGTCACG CTGCACAGAT 301 GAGGCCCGTG TGGCAGGTGG TCCCAGGAAC GAACTCGCCT CCCGCCAGCC CCCTGGGCCT 361 TCCATGGCCC CAGCCCCTTC CTATGCAGAC ACCCCTCACC CCTCTCTGGC CCTGCTTCAA 421 GCCCCCCTTC CCCGCCGTGT GGGCTTCTCG CTGTCCCCTA AGCCTTCGAT GTCCCCTCTG 481 AGCCACCGCG GCCACGGCCA ACAGGGATGC CTCCCTCACC AGCGCCTCCT GATAGCTCTG 541 GGCCTGAGCT CGGTAGAGAA ATGGAAGAGG AAGGTATATG CAGTGTTTGA CTGTCTCTGT 601 TTCTTGTCTC ACGTCACAAA ACAAGACTGA ATTTGGATTT CTGAACGCGA CTGTGTTTTC 661 CTCGGGAGGA TCTCTTGATC CCAGGAGGTA GAGGTTGCAG TGAGCCCAGA TCGCGCCACT 721 GCACTCCAGC CTGGGTGACA AAGCAGACTC TGTCTCGAAA AAACATACAT TGAAAAAGGC 781 AGAAGATTTG AACAGATACA TCAAAAAAAA GATAGACAAA TAGCAAATAA GCACTTGAAC 841 AGGTGCTCAG CATCGTTCGT TGTCAGAGGA ATGCACACGA AAACCGCAGC GACAGCGACT 901 AGAACAGCCA GGTGCTGAGG AGGGTGCGGA GCCCCTGGAA CTCACCCGTG CTGCTGAGAA 961 CACAAATGCT GCATCCGCTT TGGAAAGCAG CTTGGGAGTT GCATGTGAAA TTCAGCATTT1021 ACCACACGGC CAGCAGTTCT GCTTTGGTTA TTCTACTCCA GAGTTTCCAC TGGGGGTCCT1081 TTATGATTTC GTCTCTTCTA TCATTTTTTT GGTATAGATG GGGGTCTCGC TATTTGGATT1141 ATTGTTGCAG GCGTGTTTGG GGTTTTTGAG TAGTGGTAGT GTCTGAGGTC AGTCAGGGTT1201 GTTCTGGCCC CAGCAGGGCT CTTCGTAGCT TTTCCTGTGC AGGTGAACAA GCCTGCGGTT1261 TCACTTGTTT CTCTTAACTT AAAGGAACTG TTGTTCCCAA GAGCAGTCTT GGGCTGAACT1321 TTCAAATAAA ATGAGTTTCC TCAGGGAGCT TCAGAGCTCT TTCCTTATGG ACGGCCTCTC1381 TCCCCAGGCT GATTTCTCTG CACCACCCTT CTGGGCACTG GGTAAGACAG CAGCCTCTGA1441 TCTTCTTGGC CTGGCTTTCC CAGCATGGGT GCTCTACCCT ACTGTTTTAA CCTAGAAAGC1501 CTGAACTGTA TTTAAAACTT GTGGTTTTTA AGGCCAGGCA CAGTGGCTCA TGCCTGTAAT1561 CCCAGCACCT TGGGAAGCCA AGGTGGGTGG ATCACTTATG GTCAGGAGTT CAAGACCAGC1621 CTGACCAACC TGGTGAAAGC CTGTCTCTAC TAAAAATATA AAAATAAGCC GGGCGTGGTG1681 GCACATGCCT GTAATACCAG CTACCCAGGA AGCTGAGGCA GGAGAATTGC TTGAACCCAG1741 GAGGCGGAGG TTGCAGTGAG CCAAGATGGC ACCACTGCAC TCCAGCCTGG GCGACAGCGA1801 GACTCCATAT AAAAAAAAAA AAAAAAAA

B: aminoacid sequence (SEQ ID NO:29) length: 104 amino acid/11 MLCEWKRGLL WKPWGGAFRL RGRPRICPPP SPGPHSEDAG HAAQMRPVWQ VVPGTNSPPA61 SPLGLPWPQP LPMQTPLTPL WPCFKPPFPA VWASRCPLSL RCPL

C. Nucleotide and amino acid composite sequence (SEQ ID NO:30)

Clone number: PP8038

Start code: 167 ATG stop coding: 479 TGA

：11558.07 1 G AGA CAA GAA CCT GGC TGA AGA AAA CTT GGT CCA AAC TGC ATC AGA 46 47 GGT GGG GGT GGT CGC TGT TCC CAA GGG AAA GGT CCT GCT TAA ACA GGT 94 95 GCT TTG TGA GTG GAA ACG TGG CCA GAG TGC GGC GGG TGC TTT GTG AGT 142143 GGA AAT GTG GCC AGA GTG CGG CGG ATG CTT TGT GAG TGG AAA CGT GGC 190 1 Met Leu Cys Glu Trp Lys Arg Gly 8191 CTT CTC TGG AAG CCC TGG GGA GGG GCT TTC CGA CTG AGA GGA AGG CCT 238 9 Leu Leu Trp Lys Pro Trp Gly Gly Ala Phe Arg Leu Arg Gly Arg Pro 24239 CGC ATC TGC CCA CCG CCC AGT CCT GGG CCT CAC AGT GAG GAT GCA GGT 286 25 Arg Ile Cys Pro Pro Pro Ser Pro Gly Pro His Ser Glu Asp Ala Gly 40 287 CAC GCT GCA CAG ATG AGG CCC GTG TGG CAG GTG GTC CCA GGA ACG AAC 334 41 His Ala Ala Gln Met Arg Pro Val Trp Gln Val Val Pro Gly Thr Asn 56 335 TCG CCT CCC GCC AGC CCC CTG GGC CTT CCA TGG CCC CAG CCC CTT CCT 382 57 Ser Pro Pro Ala Ser Pro Leu Gly Leu Pro Trp Pro Gln Pro Leu Pro 72 383 ATG CAG ACA CCC CTC ACC CCT CTC TGG CCC TGC TTC AAG CCC CCC TTC 430 73 Met Gln Thr Pro Leu Thr Pro Leu Trp Pro Cys Phe Lys Pro Pro Phe 88 431 CCC GCC GTG TGG GCT TCT CGC TGT CCC CTA AGC CTT CGA TGT CCC CTC 478 89 Pro Ala Val Trp Ala Ser Arg Cys Pro Leu Ser Leu Arg Cys Pro Leu 104 479 TGA GCC ACC GCG GCC ACG GCC AAC AGG GAT GCC TCC CTC ACC AGC GCC 526 105 *** 105 527 TCC TGA TAG CTC TGG GCC TGA GCT CGG TAG AGA AAT GGA AGA GGA AGG 574 575 TAT ATG CAG TGT TTG ACT GTC TCT GTT TCT TGT CTC ACG TCA CAA AAC 622 623 AAG ACT GAA TTT GGA TTT CTG AAC GCG ACT GTG TTT TCC TCG GGA GGA 670 671 TCT CTT GAT CCC AGG AGG TAG AGG TTG CAG TGA GCC CAG ATC GCG CCA 718 719 CTG CAC TCC AGC CTG GGT GAC AAA GCA GAC TCT GTC TCG AAA AAA CAT 766 767 ACA TTG AAA AAG GCA GAA GAT TTG AAC AGA TAC ATC AAA AAA AAG ATA 814 815 GAC AAA TAG CAA ATA AGC ACT TGA ACA GGT GCT CAG CAT CGT TCG TTG 862 863 TCA GAG GAA TGC ACA CGA AAA CCG CAG CGA CAG CGA CTA GAA CAG CCA 910 911 GGT GCT GAG GAG GGT GCG GAG CCC CTG GAA CTC ACC CGT GCT GCT GAG 958 959 AAC ACA AAT GCT GCA TCC GCT TTG GAA AGC AGC TTG GGA GTT GCA TGT 10061007 GAA ATT CAG CAT TTA CCA CAC GGC CAG CAG TTC TGC TTT GGT TAT TCT 10541055 ACT CCA GAG TTT CCA CTG GGG GTC CTT TAT GAT TTC GTC TCT TCT ATC 11021103 ATT TTT TTG GTA TAG ATG GGG GTC TCG CTA TTT GGA TTA TTG TTG CAG 11501151 GCG TGT TTG GGG TTT TTG AGT AGT GGT AGT GTC TGA GGT CAG TCA GGG 11981199 TTG TTC TGG CCC CAG CAG GGC TCT TCG TAG CTT TTC CTG TGC AGG TGA 12461247 ACA AGC CTG CGG TTT CAC TTG TTT CTC TTA ACT TAA AGG AAC TGT TGT 12941295 TCC CAA GAG CAG TCT TGG GCT GAA CTT TCA AAT AAA ATG AGT TTC CTC 13421343 AGG GAG CTT CAG AGC TCT TTC CTT ATG GAC GGC CTC TCT CCC CAG GCT 13901391 GAT TTC TCT GCA CCA CCC TTC TGG GCA CTG GGT AAG ACA GCA GCC TCT 14381439 GAT CTT CTT GGC CTG GCT TTC CCA GCA TGG GTG CTC TAC CCT ACT GTT 14861487 TTA ACC TAG AAA GCC TGA ACT GTA TTT AAA ACT TGT GGT TTT TAA GGC 15341535 CAG GCA CAG TGG CTC ATG CCT GTA ATC CCA GCA CCT TGG GAA GCC AAG 15821583 GTG GGT GGA TCA CTT ATG GTC AGG AGT TCA AGA CCA GCC TGA CCA ACC 16301631 TGG TGA AAG CCT GTC TCT ACT AAA AAT ATA AAA ATA AGC CGG GCG TGG 16781679 TGG CAC ATG CCT GTA ATA CCA GCT ACC CAG GAA GCT GAG GCA GGA GAA 17261727 TTG CTT GAA CCC AGG AGG CGG AGG TTG CAG TGA GCC AAG ATG GCA CCA 17741775 CTG CAC TCC AGC CTG GGC GAC AGC GAG ACT CCA TAT AAA AAA AAA AAA 18221823 AAA AAA 1828

All quote in this application as a reference at all documents that the present invention mentions, just quoted as a reference separately as each piece document.Should be understood that in addition those skilled in the art can make various changes or modifications the present invention after having read above-mentioned teachings of the present invention, these equivalent form of values fall within the application's appended claims institute restricted portion equally.

Claims (10)

1. isolating people's albumen with cancer suppressing function, it is characterized in that it comprises the polypeptide of the aminoacid sequence with the group of being selected from down: SEQ ID NO:2, SEQ ID NO:5, SEQ ID NO:8, SEQ ID NO:11, SEQ ID NO:14, SEQID NO:17, SEQ ID NO:20, SEQ ID NO:23, SEQ ID NO:26, SEQ ID NO:29;

Or its conservative property variation polypeptide or its active fragments or its reactive derivative.

2. polypeptide as claimed in claim 1, it is characterized in that this polypeptide is the polypeptide with aminoacid sequence of the group of being selected from down: SEQ ID NO:2, SEQ ID NO:5, SEQ ID NO:8, SEQ ID NO:11, SEQ ID NO:14, SEQ ID NO:17, SEQ ID NO:20, SEQ ID NO:23, SEQ ID NO:26, SEQ ID NO:29.

3. isolating polynucleotide is characterized in that, it comprises a nucleotide sequence, and this nucleotide sequence is shown at least 85% homogeny with a kind of nucleotides sequence that is selected from down group:

(a) coding is as the polynucleotide of polypeptide as described in claim 1 and 2;

(b) with polynucleotide (a) complementary polynucleotide.

4. polynucleotide as claimed in claim 3, it is characterized in that the polypeptide of this polynucleotide encoding has the aminoacid sequence of the group of being selected from down: SEQ ID NO:2, SEQ ID NO:5, SEQ ID NO:8, SEQ ID NO:11, SEQ ID NO:14, SEQ ID NO:17, SEQ ID NO:20, SEQ ID NO:23, SEQ ID NO:26, SEQ ID NO:29.

5. polynucleotide as claimed in claim 3 is characterized in that, the sequence of these polynucleotide is selected from down group:

Coding region sequence or the full length sequence of SEQ ID NO:3, SEQ ID NO:6, SEQ ID NO:9, SEQ ID NO:12, SEQ ID NO:15, SEQ ID NO:18, SEQ ID NO:21, SEQ ID NO:24, SEQ ID NO:27, SEQ ID NO:30.

6. a carrier is characterized in that, it contains the described polynucleotide of claim 3.

7. a genetically engineered host cell is characterized in that, it is a kind of host cell that is selected from down group:

(a) host cell that transforms or transduce with the described carrier of claim 6;

(b) host cell that transforms or transduce with the described polynucleotide of claim 3.

8. the preparation method of the polypeptide of the people's protein-active with cancer suppressing function is characterized in that this method comprises:

(a) have under the proteic condition of people of cancer suppressing function suitable the expression, cultivate the described host cell of claim 7;

(b) from culture, isolate the polypeptide of people's protein-active with cancer suppressing function.

9. energy and the described people's protein-specific bonded antibody of claim 1 with cancer suppressing function.

10. a pharmaceutical composition is characterized in that, it contains the described polypeptide of claim 1 and the pharmaceutically acceptable carrier of safe and effective amount.